{"gene":"CXCL10","run_date":"2026-04-28T17:28:53","timeline":{"discoveries":[{"year":1985,"finding":"CXCL10 (IP-10) was identified as an IFN-γ-inducible early-response gene encoding a protein with homology to platelet factor-4 and β-thromboglobulin (CXC chemokine family); its mRNA is induced within 30 min of IFN-γ treatment with >30-fold accumulation, and increased transcription contributes to this accumulation.","method":"Molecular cloning, Northern blot, nuclear run-on transcription assay","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 — original cloning with multiple orthogonal methods; foundational, highly cited","pmids":["3925348"],"is_preprint":false},{"year":1990,"finding":"CRG-2, the mouse homologue of human IP-10/CXCL10, encodes a 98-amino-acid secreted protein (21-residue signal peptide) of the PF4 family; its mRNA is induced by IFN-α, IFN-β, and IFN-γ as well as LPS, peaks at 3–6 h after IFN-γ, and accumulation is not blocked by cycloheximide (primary response gene).","method":"cDNA library screening, differential hybridization, Northern blot, cycloheximide experiments, 5′-flanking region isolation","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — reconstitution-level molecular characterization; foundational paper with multiple orthogonal methods","pmids":["2118520"],"is_preprint":false},{"year":1995,"finding":"CXCL10 (IP-10) is a potent inhibitor of angiogenesis in vivo; it profoundly inhibited bFGF-induced neovascularization in a Matrigel model and suppressed endothelial cell differentiation into tubular capillary structures in vitro, without affecting endothelial cell growth, attachment, or migration.","method":"In vivo Matrigel plug assay (athymic mice), in vitro tube formation assay, endothelial cell growth/attachment/migration assays","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 — multiple in vitro and in vivo assays; highly cited foundational study","pmids":["7540647"],"is_preprint":false},{"year":1997,"finding":"CXCL10 (IP-10) and CXCL9 (Mig) share the receptor CXCR3; both chemokines are chemotactic specifically for activated (but not resting) T cells, show reciprocal desensitization on activated T cells, inhibit neovascularization, inhibit hematopoietic progenitor cells, and have anti-tumor effects, but lack neutrophil chemotactic activity.","method":"Recombinant protein chemotaxis assays, desensitization assays, receptor-sharing functional studies","journal":"Journal of leukocyte biology","confidence":"High","confidence_rationale":"Tier 2 — multiple functional assays with recombinant proteins; highly cited review synthesizing original experimental data","pmids":["9060447"],"is_preprint":false},{"year":1999,"finding":"CXCL10 receptor CXCR3 is expressed by human mesangial cells; CXCL10 binding to CXCR3 on mesangial cells induces intracellular Ca²⁺ influx and directly stimulates mesangial cell proliferation.","method":"Flow cytometry, intracellular Ca²⁺ measurement, cell proliferation assay","journal":"Journal of the American Society of Nephrology","confidence":"Medium","confidence_rationale":"Tier 2 — functional receptor assays with calcium flux and proliferation readout in primary cells","pmids":["10589690"],"is_preprint":false},{"year":1999,"finding":"Murine Crg-2 (mouse IP-10/CXCL10) expressed via recombinant vaccinia virus enhances NK cell cytolytic activity, increases mononuclear cell infiltration in liver, and is required along with IFN-α/β and IFN-γ for controlling viral replication in athymic nude mice, establishing an antiviral role in vivo.","method":"Recombinant vaccinia virus expression, in vivo viral challenge model, NK cell depletion with neutralizing antibodies, cytolytic activity assays","journal":"Journal of virology","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo epistasis via antibody depletion with defined survival and cellular phenotype readouts","pmids":["9882354"],"is_preprint":false},{"year":2000,"finding":"CXCL10 (IP-10), together with CXCL9 and CXCL11, acts as a natural antagonist for the Th2 chemokine receptor CCR3; it competes for eotaxin binding to CCR3-expressing cells and inhibits CCR3-mediated migration and Ca²⁺ signaling without inducing CCR3 internalization (pure antagonist).","method":"Radioligand competition binding assay, chemotaxis assay, Ca²⁺ mobilization assay, receptor internalization assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — multiple orthogonal biochemical assays; highly cited mechanistic study","pmids":["11110785"],"is_preprint":false},{"year":2001,"finding":"CD26/dipeptidyl peptidase IV cleaves CXCL10 (and CXCL9, CXCL11, CXCL12, CCL22) with striking selectivity; kinetic analysis shows CXCL10 is a substrate for N-terminal truncation by CD26/DPPIV, a mechanism that modulates chemokine activity in vivo.","method":"Steady-state kinetics (Km, kcat), mass spectrometry-based truncation analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — rigorous enzyme kinetics with defined substrates; highly cited","pmids":["11390394"],"is_preprint":false},{"year":2001,"finding":"CXCL10 (IP-10) has a hepatoprotective/regenerative effect during acute liver injury; its therapeutic effect is mediated through upregulation of CXCR2 on hepatocytes, with CXCR2 neutralization abrogating the effect. CXCL10 treatment of cultured hepatocytes stimulates a CXCR2-dependent proliferative response.","method":"Mouse APAP-injury model, rIP-10 administration, CXCR2 neutralizing antibody, hepatocyte proliferation assay in vitro","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 — loss-of-function (neutralizing antibody) with defined cellular and biochemical phenotype; in vitro confirmation","pmids":["11739529"],"is_preprint":false},{"year":2002,"finding":"CXCL10 is constitutively expressed in basal colonic crypts and upregulated during colitis; recombinant CXCL10 administration inhibits intestinal epithelial cell proliferation, while CXCL10 neutralization promotes crypt cell survival and protects from epithelial ulceration independent of altered immune cell infiltration.","method":"DSS colitis mouse model, anti-CXCL10 neutralizing antibody, recombinant CXCL10 administration, histology","journal":"European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 — loss- and gain-of-function in vivo with defined epithelial phenotype","pmids":["12555665"],"is_preprint":false},{"year":2003,"finding":"CXCL10 is induced in CMV-infected primary microglia through p38 MAP kinase phosphorylation (not requiring secondary protein synthesis); IL-10 suppresses CMV-induced CXCL10 by decreasing NF-κB activation (not p38 phosphorylation); viral cmvIL-10 (UL111a, spliced form) from CMV-infected astrocytes inhibits microglial CXCL10 production through the IL-10 receptor.","method":"Primary microglia infection, p38 inhibitor, cycloheximide treatment, NF-κB reporter assay, conditioned medium experiments, IL-10R blockade","journal":"Journal of virology","confidence":"Medium","confidence_rationale":"Tier 2 — multiple pathway inhibitors with defined signaling readouts","pmids":["12663757"],"is_preprint":false},{"year":2003,"finding":"An alternatively spliced variant of CXCR3, termed CXCR3-B, mediates the angiostatic activity of CXCL10 (as well as CXCL9 and CXCL11) on endothelial cells; CXCR3-B overexpression dramatically reduces DNA synthesis and upregulates apoptosis via distinct signal transduction pathways from CXCR3-A, and also acts as functional receptor for CXCL4/PF4.","method":"Alternative splicing identification, receptor transfection (CXCR3-A vs CXCR3-B), binding assays, DNA synthesis assay, apoptosis assay, signal transduction analysis, immunohistochemistry on tumor tissue","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1 — receptor reconstitution with mutagenesis/splice variants plus multiple functional readouts; highly cited","pmids":["12782716"],"is_preprint":false},{"year":2004,"finding":"CXCR3 intracellular domains differentially mediate CXCL9, CXCL10, and CXCL11 signaling: the carboxyl-terminal domain and β-arrestin1 are predominantly required for CXCL9- and CXCL10-induced internalization, while the third intracellular loop is predominantly required by CXCL11; chemotaxis and Ca²⁺ mobilization by all three ligands require both the CXCR3 C-terminus and the DRY sequence in TM3.","method":"Domain deletion/mutation analysis, β-arrestin1 dominant-negative, internalization assay, Ca²⁺ mobilization, chemotaxis assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — systematic mutagenesis with multiple functional readouts; highly cited mechanistic study","pmids":["15150261"],"is_preprint":false},{"year":2004,"finding":"EGFR-activated signaling (via NADPH oxidase/metalloproteinase pathway) during respiratory virus infection suppresses IRF1-dependent CXCL10 production in airway epithelial cells; EGFR inhibition augments IRF1 and CXCL10 levels, while EGFR activation suppresses them.","method":"Influenza/rhinovirus/RSV infection of airway epithelial cells, EGFR inhibitors, IRF1 knockdown, CXCL10 ELISA and qPCR","journal":"American journal of physiology. Lung cellular and molecular physiology","confidence":"Medium","confidence_rationale":"Tier 2 — pharmacological and genetic inhibition with defined signaling mechanism and protein readouts","pmids":["24838750"],"is_preprint":false},{"year":2004,"finding":"NF-κB κB site sequence determines cofactor specificity; for CXCL10 and other genes with two κB sites, both sites are required for activity, and the sequence of each κB site determines which coactivators productively interact with the bound NF-κB dimer rather than simply which dimer binds.","method":"Lentivirus-based κB site implantation, κB site swapping between genes, NF-κB dimer specificity assays","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 — reconstitution and mutagenesis of regulatory elements with CXCL10 as a direct experimental model; highly cited","pmids":["15315758"],"is_preprint":false},{"year":2004,"finding":"IP-10/CXCL10 attenuates bleomycin-induced pulmonary fibrosis by inhibiting fibroblast migration (chemoattractant activity) but not fibroblast proliferation; IP-10-deficient mice show dramatically increased fibroblast accumulation and fibrosis after bleomycin, while IP-10-overexpressing transgenic mice are protected.","method":"IP-10 knockout mice, IP-10 transgenic overexpression mice, bleomycin pulmonary fibrosis model, fibroblast chemotaxis/proliferation assays in vitro","journal":"American journal of respiratory cell and molecular biology","confidence":"High","confidence_rationale":"Tier 2 — reciprocal genetic (KO + transgenic) in vivo models with mechanistic in vitro follow-up","pmids":["15205180"],"is_preprint":false},{"year":2005,"finding":"CXCL10 via CXCR3 upregulates IFN-γ and T-bet expression while downregulating IL-4, IL-5, IL-13, and GATA-3 in CD4+ T cells, promoting Th1 differentiation; these effects are mediated through distinct signal transduction pathways compared with CXCL4/CXCR3-B, which has opposite effects promoting Th2 cytokines.","method":"Antigen-specific human CD4+ T-cell lines, anti-CXCR3 neutralizing antibody, qRT-PCR, flow cytometry, ELISA, IL-5/IL-13 promoter activation assay","journal":"The Journal of allergy and clinical immunology","confidence":"Medium","confidence_rationale":"Tier 2 — multiple orthogonal methods (signaling, transcription factor, cytokine) in primary human T cells","pmids":["16337473"],"is_preprint":false},{"year":2005,"finding":"CXCL10 produced preferentially by asthmatic airway smooth muscle mediates migration of human lung mast cells to airway smooth muscle predominantly through CXCR3 activation; CXCR3 is expressed on 100% of mast cells within the airway smooth muscle bundle in asthma.","method":"Immunohistochemistry of bronchial biopsies, ex vivo airway smooth muscle supernatants, mast cell chemotaxis assay, ELISA","journal":"American journal of respiratory and critical care medicine","confidence":"Medium","confidence_rationale":"Tier 2 — functional chemotaxis assay with tissue-derived supernatants plus receptor expression in primary tissue","pmids":["15879427"],"is_preprint":false},{"year":2006,"finding":"Oligomerization of CXCL10 is required for its presentation on endothelial cells and for in vivo T cell recruitment; a monomeric CXCL10 mutant retains in vitro chemotaxis activity but fails to recruit CD8+ T cells into mouse airways after intratracheal instillation and cannot bind to or enable transendothelial chemotaxis on endothelial cells, independent of reduced CXCR3 or heparin binding.","method":"Monomeric CXCL10 mutant, in vitro chemotaxis assay, intratracheal instillation in mice, molecular imaging, endothelial cell binding assay, transendothelial migration assay","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1 — defined mutant protein with multiple orthogonal in vitro and in vivo functional assays","pmids":["17082614"],"is_preprint":false},{"year":2008,"finding":"Crystal structure of mouse IP-10/CXCL10 reveals a novel tetrameric association where two conventional CXC dimers associate through N-terminal regions forming a 12-stranded elongated β-sheet (~90 Å); two heparin-binding sites are located at the interface of each β-sheet dimer; this tetramer structure differs from previously described IP-10, PF4 and NAP-2 tetramers and supports higher-order oligomer formation.","method":"X-ray crystallography, surface mapping of heparin- and receptor-binding residues","journal":"Acta crystallographica. Section D, Biological crystallography","confidence":"High","confidence_rationale":"Tier 1 — high-resolution crystal structure with functional site mapping","pmids":["18560148"],"is_preprint":false},{"year":2009,"finding":"CXCL10 signals through TLR4 (not solely CXCR3) on pancreatic β-cells to decrease viability and impair insulin secretion; CXCL10 induces sustained activation of Akt, JNK, and cleavage of PAK-2, switching Akt signaling from proliferation to apoptosis.","method":"Human islet treatment with recombinant CXCL10, TLR4 identification as receptor, Akt/JNK/PAK-2 phosphorylation assays, apoptosis assay, insulin secretion measurement","journal":"Cell metabolism","confidence":"Medium","confidence_rationale":"Tier 2 — signaling pathway dissection in primary human islets with multiple biochemical readouts; single lab","pmids":["19187771"],"is_preprint":false},{"year":2010,"finding":"CXCL10 inhibits endothelial cell proliferation through a CXCR3-independent mechanism; this inhibitory activity correlates with CXCL10's glycosaminoglycan (heparin) binding affinity rather than CXCR3 binding/signaling, as demonstrated using CXCL10 mutant panel analysis and CXCR3-deficient mouse endothelial cells.","method":"CXCR3 knockout mouse endothelial cells, CXCR3 neutralizing antibodies, CXCL10 mutant panel, FACS for CXCR3 expression, proliferation assay","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 1 — multiple orthogonal approaches (genetic KO, antibody blockade, structure-function mutant panel)","pmids":["20856926"],"is_preprint":false},{"year":2010,"finding":"CXCL10 repression in IPF lung fibroblasts involves histone deacetylation combined with histone H3 hypermethylation (via G9a/H3K9me3 and SUV39H1); this reduces transcription factor binding to the IP-10 promoter; HDAC or G9a inhibitors reverse both modifications and restore CXCL10 expression.","method":"Chromatin immunoprecipitation (ChIP), HDAC and G9a inhibitors, nuclear run-on, promoter transcription factor binding assays in IPF patient fibroblasts","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 — ChIP with pharmacological rescue in patient-derived cells; multiple epigenetic marks interrogated","pmids":["20404089"],"is_preprint":false},{"year":2011,"finding":"CXCL10 acting via CXCR3 promotes synovial fibroblast invasion through MMP-1 production, intracellular calcium influx, and actin cytoskeleton reorganization with lamellipodia formation; CXCR3 blockade reduces invasiveness by up to 77% in arthritic rat FLS and 58% in RA patient FLS.","method":"Matrigel invasion assay, anti-CXCR3 antibody, CXCR3 inhibitor AMG487, MMP ELISA, intracellular calcium assay, actin cytoskeleton imaging in primary FLS","journal":"Arthritis and rheumatism","confidence":"Medium","confidence_rationale":"Tier 2 — multiple orthogonal functional assays in primary patient-derived cells with defined signaling pathway","pmids":["21811993"],"is_preprint":false},{"year":2012,"finding":"CXCL10 mediates macrophage differentiation of activated B cells into plasma cells through a novel dialog: macrophage-derived CXCL10 (induced by B cell-derived IL-6 via STAT3 phosphorylation) drives B cell differentiation into CD138+CD38++ plasma cells, and CXCL10 amplifies IL-6 production by B cells sustaining the STAT3-mediated differentiation signal; IP-10-deficient mice show reduced NP-specific plasma cells.","method":"Human tonsil macrophage isolation, monocyte-derived macrophage co-culture with B cells, CXCL10 neutralization, STAT3 inhibition, IP-10-deficient mouse immunization model","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 — reciprocal neutralization, genetic KO in vivo model, and mechanistic signaling in primary human cells","pmids":["22987802"],"is_preprint":false},{"year":2012,"finding":"CXCL10 promotes osteolytic bone metastasis by facilitating CXCR3-expressing cancer cell recruitment to bone, promoting cancer cell adhesion to type I collagen, and augmenting RANKL-mediated osteoclast formation; cancer-bone colonization further amplifies host CXCL10 production via direct cancer cell–macrophage contact.","method":"Neutralizing CXCL10 antibody, CXCR3 knockout mice, in vivo bone metastasis model, adhesion assay to collagen I, osteoclast differentiation assay","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 — genetic and antibody loss-of-function in vivo with mechanistic in vitro follow-up","pmids":["22562465"],"is_preprint":false},{"year":2012,"finding":"CXCL10-CXCR3 axis mediates neutrophil-driven fulminant lung injury (ARDS); CXCL10 is produced by infiltrating pulmonary neutrophils via TRIF-dependent signaling; CXCL10-CXCR3 acts in an autocrine fashion on neutrophil oxidative burst and chemotaxis, amplifying pulmonary inflammation. CXCL10- or CXCR3-deficient mice show improved ARDS severity and survival.","method":"CXCL10 KO, CXCR3 KO, IFNAR1 KO, TRIF KO mice in acid-aspiration and influenza ARDS models; neutrophil CXCR3 expression analysis; in vivo survival studies","journal":"American journal of respiratory and critical care medicine","confidence":"High","confidence_rationale":"Tier 2 — multiple genetic KO models with in vivo phenotype and mechanistic signaling; highly cited","pmids":["23144331"],"is_preprint":false},{"year":2013,"finding":"CXCL10 induction during HCV infection in hepatocytes proceeds via two independent, parallel pathways through TLR3 and RIG-I pattern recognition receptors; in pure hepatocyte cultures, CXCL10 induction is independent of type I and III IFNs, whereas non-parenchymal cell-derived IFNs contribute to CXCL10 induction in mixed PHH cultures; CXCL10 protein expression positively correlates with intracellular HCV Core antigen.","method":"TLR3/RIG-I functional or non-functional hepatocyte lines, IFN neutralization, immunodepletion of non-parenchymal cells, immunofluorescence correlation analysis","journal":"Journal of hepatology","confidence":"Medium","confidence_rationale":"Tier 2 — genetic and antibody dissection of parallel pathways in primary human hepatocytes and cell lines","pmids":["23770038"],"is_preprint":false},{"year":2014,"finding":"Heparanase induction decreases CXCL10 levels in myeloma cells, and CXCL10 exerts tumor-suppressor and anti-angiogenic properties; recombinant CXCL10 attenuates myeloma and HUVEC proliferation in vitro, and CXCL10 overexpression or CXCL10-Ig fusion protein treatment markedly reduces myeloma xenograft growth in vivo.","method":"Inducible Tet-on heparanase system, soft agar colony assay, xenograft model, recombinant CXCL10 treatment, CXCL10-Ig fusion protein in vivo","journal":"Leukemia","confidence":"Medium","confidence_rationale":"Tier 2 — gain/loss of function with in vitro and in vivo endpoints in defined system","pmids":["24699306"],"is_preprint":false},{"year":2014,"finding":"MRP8/MRP14 (endogenous DAMP) induces IP-10/CXCL10 production in monocytes/macrophages via TLR4 and TRIF (not MyD88); full induction requires synergistic activation of both NF-κB and IRF3 transcription factors; MRP8/MRP14-induced chemotaxis of CXCR3+ cells depends on IP-10 production; neutralizing anti-MRP8 antibody in vivo prevents NF-κB/IRF3 activation and IP-10 production.","method":"THP-1 monocytes, TLR4 and TRIF/MyD88 pathway inhibition, NF-κB and IRF3 activation assays, CXCR3+ cell chemotaxis, mouse trauma/hemorrhagic shock model with neutralizing antibody","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 — pathway dissection with genetic/pharmacological tools confirmed in vivo","pmids":["25342131"],"is_preprint":false},{"year":2015,"finding":"MLK3 (mixed lineage kinase 3) mediates the release of CXCL10-laden extracellular vesicles from lipotoxic hepatocytes; CXCL10 is enriched in EVs from LPC-treated hepatocytes and colocalizes with EV marker CD63 in vesicular structures; MLK3 genetic deletion or pharmacological inhibition prevents CXCL10 enrichment in EVs; these CXCL10-bearing EVs induce macrophage chemotaxis, which is blocked by CXCL10-neutralizing antisera.","method":"Differential ultracentrifugation EV isolation, mass spectrometry, GFP-CXCL10/RFP-CD63 colocalization, MLK3 KO mice, MLK3 inhibitor, macrophage chemotaxis assay, CXCL10 neutralizing antisera","journal":"Hepatology","confidence":"High","confidence_rationale":"Tier 1 — reconstitution (EV isolation + functional assay) with genetic and pharmacological validation in vitro and in vivo; highly cited","pmids":["26406121"],"is_preprint":false},{"year":2017,"finding":"CXCL10 promotes hepatocellular carcinoma EMT and metastasis through MMP-2 as a downstream effector; CXCL10 overexpression enhances migration, invasion, and metastasis of HCC cells in vitro and in vivo, while CXCL10 silencing inhibits these, and microarray analysis identified MMP-2 as a downstream target of CXCL10.","method":"CXCL10 overexpression and shRNA silencing, in vitro migration/invasion assay, in vivo metastasis model, microarray analysis, MMP-2 validation","journal":"American journal of translational research","confidence":"Medium","confidence_rationale":"Tier 2 — gain and loss of function with transcriptomic identification of downstream effector","pmids":["28670372"],"is_preprint":false},{"year":2017,"finding":"CXCL10 stimulates IFN-γ-primed human monocytes to robustly produce IL-12 and IL-23 via CXCR3 receptor engagement and IκB kinase / p38 MAPK signaling pathways; in a murine colitis model, anti-CXCL10 antibody treatment suppresses local myeloid-derived inflammatory cytokine production and reduces intestinal tissue damage.","method":"Human monocyte culture, CXCR3 blocking antibody, IKK and p38 MAPK inhibitors, cytokine ELISA; innate murine colitis model with anti-CXCL10 treatment","journal":"Journal of leukocyte biology","confidence":"Medium","confidence_rationale":"Tier 2 — pharmacological pathway dissection in primary human cells with in vivo confirmation","pmids":["28899907"],"is_preprint":false},{"year":2017,"finding":"CXCL10 suppresses corneal hem- and lymph-angiogenesis through downregulation of MMP-13 (and VEGFa/c); MMP-13 is required for neovascularization but does not affect CXCL10 expression; CXCL10 and CXCR3 neutralization promotes angiogenesis, while AAV9-driven epithelial CXCL10 overexpression suppresses it.","method":"AAV9 CXCL10 overexpression, CXCL10/CXCR3 neutralization, MMP-13 inhibition, mouse corneal infection/suture neovascularization models","journal":"Angiogenesis","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo gain/loss of function with genetic/pharmacological pathway placement","pmids":["28623423"],"is_preprint":false},{"year":2018,"finding":"EZH2 and G9a cooperate and physically interact to epigenetically repress CXCL10 in IPF fibroblasts via H3K27me3 and H3K9me3 marks respectively; EZH2 knockdown reduces both EZH2/H3K27me3 and G9a/H3K9me3, and vice versa; TGF-β1 induces this interplay to repress CXCL10; EZH2/G9a inhibitors restore CXCL10 expression.","method":"ChIP, Re-ChIP, proximity ligation assay (EZH2-G9a interaction), siRNA knockdown, EZH2/G9a inhibitors, TGF-β1 treatment of primary fibroblasts","journal":"American journal of respiratory cell and molecular biology","confidence":"High","confidence_rationale":"Tier 1 — physical interaction (proximity ligation) plus reciprocal ChIP and genetic knockdown with functional restoration","pmids":["29053336"],"is_preprint":false},{"year":2019,"finding":"Viperin (RSAD2) regulates chondrogenic differentiation by influencing secretion of CXCL10, which in turn modulates TGF-β/SMAD2/3 activity; viperin-CXCL10-TGF-β/SMAD2/3 axis is disturbed in cartilage-hair hypoplasia (CHH) chondrocytes; viperin is expressed in differentiating chondrocytes and controls protein secretion.","method":"siRNA silencing of viperin, plasmid overexpression, label-free MS proteomics of secretome, CXCL10 ELISA, promoter reporter assay, TGF-β/SMAD2/3 signaling readouts, immunohistochemistry","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — multiple orthogonal methods establishing pathway axis, single lab","pmids":["30718282"],"is_preprint":false},{"year":2019,"finding":"Leishmania major virulence factor GP63 cleaves CXCL10 after amino acid A81 at the base of its C-terminal α-helix, inactivating it; GP63 shows specificity for CXCR3-binding chemokines (CXCL10 and homologs) but not CXCL8 or CCL22; cleaved CXCL10 cannot signal through CXCR3 and fails to support T cell chemotaxis in vitro; cleavage is produced by both extracellular promastigotes and intracellular amastigotes.","method":"Recombinant GP63 cleavage assay, mass spectrometry cleavage site mapping, CXCR3 chemotaxis assay, substrate specificity panel with multiple chemokines, amastigote/promastigote stage-specific analysis","journal":"Frontiers in cellular and infection microbiology","confidence":"High","confidence_rationale":"Tier 1 — precise cleavage site identified by MS, specificity panel, functional chemotaxis consequence demonstrated","pmids":["31440475"],"is_preprint":false},{"year":2020,"finding":"hCG inhibits CXCL10 expression in endometrial stromal/decidual cells by inducing EZH2-mediated H3K27me3 histone methylation at Region 4 of the CXCL10 promoter; hCG-mediated CXCL10 suppression reduces CD8 T cell recruitment to decidua.","method":"In vitro decidual cell treatment with hCG, ChIP for H3K27me3, EZH2 inhibition, CXCL10 promoter deletion analysis, CD8 T cell migration assay","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP with EZH2 inhibition and functional T cell recruitment readout","pmids":["32238853"],"is_preprint":false},{"year":2021,"finding":"Plasmodium falciparum inhibits CXCL10 synthesis in monocytes by disrupting ribosome association with CXCL10 transcripts (translational suppression); the underlying mechanism involves RNA cargo delivery into monocytes triggering RIG-I, leading to HuR binding to an AU-rich domain in the CXCL10 3′UTR; conversely, high CXCL10 levels signal P. falciparum to accelerate growth as a survival strategy.","method":"Ribosome profiling/polysome analysis, RNA cargo delivery assay, RIG-I signaling assay, RIP assay (HuR binding to CXCL10 3′UTR), AU-rich element identification, parasite growth acceleration assay","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 — mechanistic dissection at translational level with multiple molecular tools identifying specific 3′UTR element and RNA-binding protein","pmids":["34381047"],"is_preprint":false},{"year":2022,"finding":"MEK inhibitor combined with PEM/CDDP chemotherapy triggers CXCL10 secretion from cancer cells through optineurin (OPTN)-dependent mitophagy, mitochondrial DNA release, and TLR9 signaling; TLR9 or autophagy/mitophagy inhibition abolishes CXCL10 induction and anti-tumor efficacy.","method":"Drug screening, OPTN KO, TLR9 inhibition, mitophagy inhibitors, mitochondrial DNA depletion, CXCL10 ELISA, in vivo lung tumor models","journal":"Cancer cell","confidence":"High","confidence_rationale":"Tier 2 — multiple genetic and pharmacological loss-of-function tools establishing pathway in vivo and in vitro; highly cited","pmids":["35051357"],"is_preprint":false},{"year":2023,"finding":"MLKL regulates macrophage M1 polarization in acute pancreatitis through CXCL10 secretion from pancreatic acinar cells; MLKL knockout attenuates AP and reduces M1 macrophage polarization; neutralization of CXCL10 in vitro impairs conditioned-medium-driven M1 polarization, and in vivo CXCL10 neutralization reduces M1 macrophage polarization and AP severity; MLKL acts independently of RIPK3 in this pathway.","method":"Mlkl KO and Ripk3 KO mice, cerulein/LPS AP model, primary acinar cell isolation, conditioned medium, CXCL10 neutralizing antibody in vitro and in vivo, macrophage polarization assays","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 — genetic KO and antibody neutralization with defined cellular phenotype in vivo and in vitro","pmids":["36828808"],"is_preprint":false}],"current_model":"CXCL10 (IP-10) is an IFN-γ–inducible CXC chemokine that signals primarily through CXCR3 (including the alternatively spliced angiostatic CXCR3-B isoform) and, in certain contexts, through TLR4; oligomerization and glycosaminoglycan binding are required for endothelial cell presentation and in vivo T cell recruitment; the protein is subject to N-terminal truncation by CD26/DPPIV and C-terminal cleavage by pathogen proteases (e.g., Leishmania GP63) that abrogate CXCR3 signaling; its expression is epigenetically repressed by cooperative EZH2/G9a-mediated histone methylation and HDAC-mediated deacetylation at its promoter; upstream induction proceeds via parallel TLR3/RIG-I or TLR4/TRIF pathways converging on NF-κB and IRF3; CXCL10 orchestrates Th1 polarization, antiangiogenesis, fibroblast migration inhibition, plasma cell differentiation, neutrophil autocrine amplification in ARDS, and osteoclastogenesis, while also being packaged into MLK3-dependent extracellular vesicles from lipotoxic hepatocytes to drive macrophage chemotaxis."},"narrative":{"teleology":[{"year":1985,"claim":"The discovery of IP-10 as an IFN-γ-inducible early-response gene established CXCL10 as a primary interferon effector and placed it within the CXC chemokine family, providing the molecular identity needed for all subsequent functional studies.","evidence":"Molecular cloning, Northern blot, and nuclear run-on assay in IFN-γ-treated cells","pmids":["3925348"],"confidence":"High","gaps":["Receptor unknown at this point","No functional role defined beyond inducibility","Protein structure not determined"]},{"year":1997,"claim":"Identification of CXCR3 as the shared receptor for CXCL10, CXCL9, and CXCL11 resolved the receptor-specificity question and explained the selective chemotaxis for activated (but not resting) T cells.","evidence":"Recombinant protein chemotaxis assays, desensitization experiments, and receptor-sharing functional studies","pmids":["9060447"],"confidence":"High","gaps":["CXCR3 splice variants not yet recognized","Downstream signaling pathways uncharacterized","In vivo relevance of receptor specificity not demonstrated"]},{"year":2000,"claim":"Demonstrating that CXCL10 acts as a pure antagonist of the Th2 receptor CCR3 without inducing internalization revealed a dual mechanism—agonism at CXCR3 and antagonism at CCR3—that positions CXCL10 as a regulator of Th1/Th2 balance beyond simple chemotaxis.","evidence":"Radioligand competition binding, chemotaxis, Ca²⁺ mobilization, and receptor internalization assays","pmids":["11110785"],"confidence":"High","gaps":["Physiological significance of CCR3 antagonism in vivo not established","Structural basis for dual receptor interaction unknown"]},{"year":2003,"claim":"Discovery of the CXCR3-B splice variant as the receptor mediating CXCL10's angiostatic activity resolved the apparent paradox of how the same chemokine promotes T-cell chemotaxis via CXCR3-A yet inhibits endothelial cell growth via distinct signaling.","evidence":"Receptor reconstitution with CXCR3-A vs CXCR3-B transfection, DNA synthesis, and apoptosis assays","pmids":["12782716"],"confidence":"High","gaps":["Relative contribution of CXCR3-B vs GAG binding to angiostasis not resolved","CXCR3-B downstream signaling not fully mapped"]},{"year":2004,"claim":"Systematic CXCR3 domain mutagenesis and the demonstration that κB site sequence determines NF-κB cofactor specificity at the CXCL10 promoter defined the receptor-proximal and transcriptional regulatory logic governing CXCL10 signaling and expression.","evidence":"CXCR3 domain deletion/mutation analysis with β-arrestin dominant-negative; κB site swapping experiments","pmids":["15150261","15315758"],"confidence":"High","gaps":["Full signal transduction cascade from CXCR3 to effector functions not mapped","Chromatin-level regulation not yet addressed"]},{"year":2006,"claim":"Proving that CXCL10 oligomerization is required for endothelial presentation and in vivo T-cell recruitment—despite a monomeric mutant retaining in vitro chemotactic activity—established that quaternary structure gates physiological function.","evidence":"Monomeric CXCL10 mutant tested in vitro chemotaxis, intratracheal mouse instillation, and transendothelial migration assays","pmids":["17082614"],"confidence":"High","gaps":["Oligomer stoichiometry required in vivo not defined","Relationship between oligomerization and GAG binding not fully disentangled"]},{"year":2008,"claim":"The crystal structure of mouse CXCL10 revealing a novel tetramer with heparin-binding sites at dimer interfaces provided the first atomic framework for understanding oligomer-dependent GAG presentation.","evidence":"X-ray crystallography with surface mapping of heparin- and receptor-binding residues","pmids":["18560148"],"confidence":"High","gaps":["Human CXCL10 structure in complex with CXCR3 not available","Higher-order oligomers on GAG surfaces not structurally resolved"]},{"year":2009,"claim":"Identification of TLR4 as an alternative CXCL10 receptor on pancreatic β-cells that switches Akt signaling from proliferative to apoptotic expanded the receptor repertoire beyond CXCR3 and revealed context-dependent signaling outcomes.","evidence":"Recombinant CXCL10 treatment of human islets, TLR4 identification, Akt/JNK/PAK-2 phosphorylation and apoptosis assays","pmids":["19187771"],"confidence":"Medium","gaps":["TLR4 as a direct CXCL10 receptor awaits independent replication","Structural basis for CXCL10–TLR4 binding unknown","Relative contribution of TLR4 vs CXCR3 on β-cells not quantified"]},{"year":2010,"claim":"Demonstrating that CXCL10's antiproliferative effect on endothelial cells is CXCR3-independent and correlates with GAG-binding affinity, together with the discovery that cooperative EZH2/G9a histone methylation and HDAC-dependent deacetylation silence CXCL10 in fibrotic lung fibroblasts, defined both receptor-independent functional and epigenetic regulatory mechanisms.","evidence":"CXCR3 KO endothelial cells plus mutant panel; ChIP with HDAC/G9a inhibitor rescue in IPF fibroblasts","pmids":["20856926","20404089"],"confidence":"High","gaps":["Identity of the GAG-dependent receptor or mechanism on endothelial cells not determined","In vivo relevance of epigenetic silencing for fibrosis progression not causally tested"]},{"year":2012,"claim":"Three studies collectively broadened CXCL10's effector biology: it drives macrophage-dependent B-cell-to-plasma-cell differentiation through a CXCL10–IL-6–STAT3 feedforward loop, promotes osteoclastogenesis in bone metastasis, and amplifies ARDS through an autocrine CXCR3 loop on neutrophils—demonstrating roles far beyond T-cell chemotaxis.","evidence":"Macrophage/B-cell co-culture with CXCL10 neutralization and IP-10 KO mice; CXCR3 KO mice in bone metastasis model; CXCL10/CXCR3/TRIF KO mice in acid aspiration and influenza ARDS models","pmids":["22987802","22562465","23144331"],"confidence":"High","gaps":["CXCL10's role in plasma cell differentiation in non-immunization settings not tested","Autocrine neutrophil loop specificity vs other CXCR3 ligands not fully delineated"]},{"year":2015,"claim":"Discovery that lipotoxic hepatocytes release CXCL10 in MLK3-dependent extracellular vesicles that recruit macrophages revealed a vesicular delivery mode for this chemokine, distinct from conventional secretion.","evidence":"EV isolation, GFP-CXCL10/RFP-CD63 colocalization, MLK3 KO mice, macrophage chemotaxis assay with CXCL10-neutralizing antisera","pmids":["26406121"],"confidence":"High","gaps":["Proportion of CXCL10 delivered via EVs vs soluble secretion in vivo unknown","EV-CXCL10 receptor engagement mechanism on macrophages not defined"]},{"year":2018,"claim":"Demonstrating that EZH2 and G9a physically interact and reciprocally depend on each other to co-silence CXCL10 via H3K27me3 and H3K9me3 under TGF-β1 defined the full epigenetic repression complex and its upstream signal.","evidence":"Re-ChIP, proximity ligation assay, reciprocal siRNA knockdown, EZH2/G9a inhibitors in primary IPF fibroblasts","pmids":["29053336"],"confidence":"High","gaps":["Whether this EZH2/G9a complex is recruited by specific DNA-binding factors remains unknown","Generalizability beyond fibroblasts not established"]},{"year":2019,"claim":"Identification of Leishmania GP63 as a specific C-terminal protease that cleaves CXCL10 after A81 to abolish CXCR3 signaling established pathogen-mediated inactivation as a immune evasion strategy, complementing the known N-terminal truncation by CD26/DPPIV.","evidence":"Recombinant GP63 cleavage, mass spectrometry site mapping, chemokine specificity panel, CXCR3 chemotaxis assay","pmids":["31440475"],"confidence":"High","gaps":["In vivo contribution of GP63-mediated CXCL10 cleavage to Leishmania pathogenesis not quantified","Whether host proteases cleave at the same C-terminal site is unknown"]},{"year":2021,"claim":"Demonstrating that Plasmodium falciparum suppresses CXCL10 translation through RNA cargo-triggered RIG-I/HuR binding to the CXCL10 3′UTR AU-rich element revealed a post-transcriptional immune evasion mechanism distinct from transcriptional or proteolytic regulation.","evidence":"Ribosome profiling, RIP assay for HuR–CXCL10 3′UTR binding, RIG-I pathway dissection","pmids":["34381047"],"confidence":"High","gaps":["Identity of the RNA cargo species from P. falciparum not defined","Whether HuR-mediated translational suppression extends to other CXCR3 ligands not tested"]},{"year":2022,"claim":"Linking MEK inhibitor/chemotherapy-induced CXCL10 secretion to optineurin-dependent mitophagy, mitochondrial DNA release, and TLR9 signaling established an entirely new induction pathway originating from mitochondrial stress rather than canonical interferon signaling.","evidence":"OPTN KO, TLR9 inhibition, mitophagy inhibitors, mitochondrial DNA depletion, in vivo lung tumor models","pmids":["35051357"],"confidence":"High","gaps":["Whether this pathway operates in non-cancer cell types unknown","Relative contribution of mitophagy-derived vs IFN-driven CXCL10 in tumors not quantified"]},{"year":null,"claim":"Major unresolved questions include the identity of the receptor mediating CXCR3-independent angiostatic signaling via GAG binding, the structural basis of CXCL10–CXCR3 and CXCL10–TLR4 interactions, and whether EV-packaged CXCL10 engages receptors differently from the soluble form.","evidence":"","pmids":[],"confidence":"Low","gaps":["No co-crystal structure of CXCL10 with any receptor","GAG-dependent antiproliferative receptor on endothelial cells unidentified","In vivo quantitative partitioning between EV-bound and soluble CXCL10 unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[0,3,6,11,16,18,24,25,26]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[6,21]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,1,18,19,30]},{"term_id":"GO:0031410","term_label":"cytoplasmic vesicle","supporting_discovery_ids":[30]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[3,5,16,24,26,29,32,38]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[4,11,12,20,23]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[14,22,34,37]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[22,34,37]},{"term_id":"R-HSA-5653656","term_label":"Vesicle-mediated transport","supporting_discovery_ids":[30]}],"complexes":[],"partners":["CXCR3","CCR3","TLR4","DPP4","EZH2","G9A","HUR","MLK3"],"other_free_text":[]},"mechanistic_narrative":"CXCL10 (IP-10) is an interferon-inducible CXC chemokine that functions as a central mediator of Th1-type immune responses, angiostasis, and tissue remodeling by signaling primarily through CXCR3 on activated T cells, NK cells, monocytes, and other CXCR3-expressing cell types, while also acting as a natural antagonist of the Th2-associated receptor CCR3 [PMID:9060447, PMID:11110785, PMID:16337473]. Oligomerization is required for glycosaminoglycan-dependent endothelial presentation and in vivo T-cell recruitment, whereas CXCL10's angiostatic activity on endothelial cells is mediated through the CXCR3-B splice variant and, independently, through glycosaminoglycan binding [PMID:17082614, PMID:12782716, PMID:20856926]. Transcriptional induction proceeds via parallel TLR3/RIG-I or TLR4/TRIF pathways converging on NF-κB and IRF3, while epigenetic silencing involves cooperative EZH2/G9a-mediated histone methylation and HDAC-dependent deacetylation at the CXCL10 promoter; post-translationally, N-terminal truncation by CD26/DPPIV and C-terminal cleavage by the Leishmania protease GP63 abrogate CXCR3 signaling [PMID:25342131, PMID:15315758, PMID:29053336, PMID:11390394, PMID:31440475]. Beyond canonical chemotaxis, CXCL10 drives macrophage-dependent plasma cell differentiation, promotes osteoclastogenesis, amplifies neutrophil oxidative burst in an autocrine CXCR3 loop during ARDS, inhibits fibroblast migration to limit pulmonary fibrosis, and is released in MLK3-dependent extracellular vesicles from lipotoxic hepatocytes to recruit macrophages [PMID:22987802, PMID:22562465, PMID:23144331, PMID:15205180, PMID:26406121]."},"prefetch_data":{"uniprot":{"accession":"P02778","full_name":"C-X-C motif chemokine 10","aliases":["10 kDa interferon gamma-induced protein","Gamma-IP10","IP-10","Small-inducible cytokine B10"],"length_aa":98,"mass_kda":10.9,"function":"Pro-inflammatory cytokine that is involved in a wide variety of processes such as chemotaxis, differentiation, and activation of peripheral immune cells, regulation of cell growth, apoptosis and modulation of angiostatic effects (PubMed:11157474, PubMed:22652417, PubMed:7540647). Plays thereby an important role during viral infections by stimulating the activation and migration of immune cells to the infected sites (By similarity). Mechanistically, binding of CXCL10 to the CXCR3 receptor activates G protein-mediated signaling and results in downstream activation of phospholipase C-dependent pathway, an increase in intracellular calcium production and actin reorganization (PubMed:12750173, PubMed:19151743). In turn, recruitment of activated Th1 lymphocytes occurs at sites of inflammation (PubMed:12663757, PubMed:12750173). Activation of the CXCL10/CXCR3 axis also plays an important role in neurons in response to brain injury for activating microglia, the resident macrophage population of the central nervous system, and directing them to the lesion site. This recruitment is an essential element for neuronal reorganization (By similarity)","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/P02778/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CXCL10","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CXCL10","total_profiled":1310},"omim":[{"mim_id":"621401","title":"DEAH-BOX HELICASE 35; DHX35","url":"https://www.omim.org/entry/621401"},{"mim_id":"620430","title":"AUTOIMMUNE DISEASE, MULTISYSTEM, INFANTILE-ONSET, 3; ADMIO3","url":"https://www.omim.org/entry/620430"},{"mim_id":"619872","title":"IMMUNODEFICIENCY 101 (VARICELLA ZOSTER VIRUS-SPECIFIC); IMD101","url":"https://www.omim.org/entry/619872"},{"mim_id":"618852","title":"AUTOINFLAMMATION WITH EPISODIC FEVER AND LYMPHADENOPATHY; AIEFL","url":"https://www.omim.org/entry/618852"},{"mim_id":"618172","title":"LONG NONCODING RNA UPREGULATOR OF ANTIVIRAL RESPONSE INTERFERON SIGNALING; LUARIS","url":"https://www.omim.org/entry/618172"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"lymphoid tissue","ntpm":90.0}],"url":"https://www.proteinatlas.org/search/CXCL10"},"hgnc":{"alias_symbol":["IFI10","IP-10","crg-2","mob-1","C7","gIP-10"],"prev_symbol":["INP10","SCYB10"]},"alphafold":{"accession":"P02778","domains":[{"cath_id":"2.40.50.40","chopping":"22-95","consensus_level":"high","plddt":92.3239,"start":22,"end":95}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P02778","model_url":"https://alphafold.ebi.ac.uk/files/AF-P02778-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P02778-F1-predicted_aligned_error_v6.png","plddt_mean":89.56},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CXCL10","jax_strain_url":"https://www.jax.org/strain/search?query=CXCL10"},"sequence":{"accession":"P02778","fasta_url":"https://rest.uniprot.org/uniprotkb/P02778.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P02778/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P02778"}},"corpus_meta":[{"pmid":"9060447","id":"PMC_9060447","title":"Mig and IP-10: CXC chemokines that target lymphocytes.","date":"1997","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/9060447","citation_count":655,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19105984","id":"PMC_19105984","title":"CXCL10 and autoimmune diseases.","date":"2008","source":"Autoimmunity reviews","url":"https://pubmed.ncbi.nlm.nih.gov/19105984","citation_count":287,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19187771","id":"PMC_19187771","title":"CXCL10 impairs beta cell function and viability in diabetes through TLR4 signaling.","date":"2009","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/19187771","citation_count":185,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35051357","id":"PMC_35051357","title":"MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells.","date":"2022","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/35051357","citation_count":182,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15205180","id":"PMC_15205180","title":"Inhibition of pulmonary fibrosis by the chemokine IP-10/CXCL10.","date":"2004","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15205180","citation_count":166,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2118520","id":"PMC_2118520","title":"Identification of CRG-2. An interferon-inducible mRNA predicted to encode a murine monokine.","date":"1990","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/2118520","citation_count":163,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29893515","id":"PMC_29893515","title":"CXCL9, CXCL10, CXCL11, and their receptor (CXCR3) in neuroinflammation and neurodegeneration.","date":"2018","source":"Advances in clinical and experimental medicine : official organ Wroclaw Medical University","url":"https://pubmed.ncbi.nlm.nih.gov/29893515","citation_count":161,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11912115","id":"PMC_11912115","title":"Chemokines and chemokine receptors in inflammatory demyelinating neuropathies: a central role for IP-10.","date":"2002","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/11912115","citation_count":119,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24868552","id":"PMC_24868552","title":"The multifaceted functions of CXCL10 in cardiovascular disease.","date":"2014","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/24868552","citation_count":114,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26042934","id":"PMC_26042934","title":"Oncogenic CXCL10 signalling drives metastasis development and poor clinical outcome.","date":"2015","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/26042934","citation_count":112,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11777981","id":"PMC_11777981","title":"CCL7 and CXCL10 orchestrate oxidative stress-induced neutrophilic lung inflammation.","date":"2002","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/11777981","citation_count":104,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22562465","id":"PMC_22562465","title":"CXCL10 promotes osteolytic bone metastasis by enhancing cancer outgrowth and osteoclastogenesis.","date":"2012","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/22562465","citation_count":103,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24529741","id":"PMC_24529741","title":"CXCR3, CXCL10 and type 1 diabetes.","date":"2014","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/24529741","citation_count":102,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10589690","id":"PMC_10589690","title":"Role for interactions between IP-10/Mig and CXCR3 in proliferative glomerulonephritis.","date":"1999","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/10589690","citation_count":102,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12555665","id":"PMC_12555665","title":"Blockade of CXCL10 protects mice from acute colitis and enhances crypt cell survival.","date":"2002","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12555665","citation_count":99,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7679604","id":"PMC_7679604","title":"Galanin receptor antagonists M40 and C7 block galanin-induced feeding.","date":"1993","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/7679604","citation_count":94,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24699306","id":"PMC_24699306","title":"Heparanase enhances myeloma progression via CXCL10 downregulation.","date":"2014","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/24699306","citation_count":92,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16337473","id":"PMC_16337473","title":"CXCR3-mediated opposite effects of CXCL10 and CXCL4 on TH1 or TH2 cytokine production.","date":"2005","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16337473","citation_count":91,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23092582","id":"PMC_23092582","title":"The interaction between CXCL10 and cytokines in chronic inflammatory arthritis.","date":"2012","source":"Autoimmunity reviews","url":"https://pubmed.ncbi.nlm.nih.gov/23092582","citation_count":90,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9882354","id":"PMC_9882354","title":"The interferon-inducible chemokines MuMig and Crg-2 exhibit antiviral activity In vivo.","date":"1999","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/9882354","citation_count":86,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30472104","id":"PMC_30472104","title":"IP-10 is highly involved in HIV infection.","date":"2018","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/30472104","citation_count":84,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20856926","id":"PMC_20856926","title":"CXCL10 can inhibit endothelial cell proliferation independently of CXCR3.","date":"2010","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/20856926","citation_count":83,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15307834","id":"PMC_15307834","title":"High pretransplant serum levels of CXCL10/IP-10 are related to increased risk of renal allograft failure.","date":"2004","source":"American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons","url":"https://pubmed.ncbi.nlm.nih.gov/15307834","citation_count":83,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17082614","id":"PMC_17082614","title":"Oligomerization of CXCL10 is necessary for endothelial cell presentation and in vivo activity.","date":"2006","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/17082614","citation_count":82,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21811993","id":"PMC_21811993","title":"CXCL10 and its receptor CXCR3 regulate synovial fibroblast invasion in rheumatoid arthritis.","date":"2011","source":"Arthritis and rheumatism","url":"https://pubmed.ncbi.nlm.nih.gov/21811993","citation_count":78,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20404089","id":"PMC_20404089","title":"Repression of IP-10 by interactions between histone deacetylation and hypermethylation in idiopathic pulmonary fibrosis.","date":"2010","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/20404089","citation_count":78,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22815829","id":"PMC_22815829","title":"An IP-10 (CXCL10)-derived peptide inhibits angiogenesis.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22815829","citation_count":77,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12663757","id":"PMC_12663757","title":"CXCL10 production from cytomegalovirus-stimulated microglia is regulated by both human and viral interleukin-10.","date":"2003","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/12663757","citation_count":77,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22987802","id":"PMC_22987802","title":"Macrophages induce differentiation of plasma cells through CXCL10/IP-10.","date":"2012","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22987802","citation_count":73,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32243054","id":"PMC_32243054","title":"Regio- and Stereoselective Steroid Hydroxylation at C7 by Cytochrome P450 Monooxygenase Mutants.","date":"2020","source":"Angewandte Chemie (International ed. in English)","url":"https://pubmed.ncbi.nlm.nih.gov/32243054","citation_count":70,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17287085","id":"PMC_17287085","title":"Induction of IP-10 (CXCL10) in astrocytes following Japanese encephalitis.","date":"2007","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/17287085","citation_count":68,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11739529","id":"PMC_11739529","title":"IFN-gamma-inducible protein-10 (CXCL10) is hepatoprotective during acute liver injury through the induction of CXCR2 on hepatocytes.","date":"2001","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/11739529","citation_count":68,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36366543","id":"PMC_36366543","title":"CXCL10 Chemokine: A Critical Player in RNA and DNA Viral Infections.","date":"2022","source":"Viruses","url":"https://pubmed.ncbi.nlm.nih.gov/36366543","citation_count":67,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28899907","id":"PMC_28899907","title":"A novel function of CXCL10 in mediating monocyte production of proinflammatory cytokines.","date":"2017","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/28899907","citation_count":58,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32089645","id":"PMC_32089645","title":"Role of Chemokine (C-X-C Motif) Ligand 10 (CXCL10) in Renal Diseases.","date":"2020","source":"Mediators of inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/32089645","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10409110","id":"PMC_10409110","title":"Cholecystokinin induction of mob-1 chemokine expression in pancreatic acinar cells requires NF-kappaB activation.","date":"1999","source":"The American journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/10409110","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25342131","id":"PMC_25342131","title":"Injury-induced MRP8/MRP14 stimulates IP-10/CXCL10 in monocytes/macrophages.","date":"2014","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/25342131","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9705166","id":"PMC_9705166","title":"Chemokine IP-10 expression in cultured human keratinocytes.","date":"1998","source":"Archives of dermatological research","url":"https://pubmed.ncbi.nlm.nih.gov/9705166","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29053336","id":"PMC_29053336","title":"Interplay between EZH2 and G9a Regulates CXCL10 Gene Repression in Idiopathic Pulmonary Fibrosis.","date":"2018","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/29053336","citation_count":50,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24838750","id":"PMC_24838750","title":"EGFR activation suppresses respiratory virus-induced IRF1-dependent CXCL10 production.","date":"2014","source":"American journal of physiology. Lung cellular and molecular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/24838750","citation_count":50,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26318079","id":"PMC_26318079","title":"CXCL10 in psoriasis.","date":"2015","source":"Advances in medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/26318079","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30109979","id":"PMC_30109979","title":"Chemokine CXCL10 and Coronavirus-Induced Neurologic Disease.","date":"2018","source":"Viral immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30109979","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15465611","id":"PMC_15465611","title":"Interferon-beta induces transient systemic IP-10/CXCL10 chemokine release in patients with multiple sclerosis.","date":"2004","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/15465611","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25386381","id":"PMC_25386381","title":"Cognitive Status Correlates with CXCL10/IP-10 Levels in Parkinson's Disease.","date":"2014","source":"Parkinson's disease","url":"https://pubmed.ncbi.nlm.nih.gov/25386381","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17671396","id":"PMC_17671396","title":"Blockade of IP-10/CXCR3 promotes progressive renal fibrosis.","date":"2007","source":"Nephron. Experimental nephrology","url":"https://pubmed.ncbi.nlm.nih.gov/17671396","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27650493","id":"PMC_27650493","title":"CXCL13, CXCL10 and CXCL8 as Potential Biomarkers for the Diagnosis of Neurosyphilis Patients.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27650493","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17505511","id":"PMC_17505511","title":"Expression of IP-10 related to angiogenesis in uterine cervical cancers.","date":"2007","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/17505511","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18037659","id":"PMC_18037659","title":"Caries-related bacteria and cytokines induce CXCL10 in dental pulp.","date":"2007","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/18037659","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24890566","id":"PMC_24890566","title":"The role of CXCL10 in the pathogenesis of experimental septic shock.","date":"2014","source":"Critical care (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/24890566","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28670372","id":"PMC_28670372","title":"CXCL10 accelerates EMT and metastasis by MMP-2 in hepatocellular carcinoma.","date":"2017","source":"American journal of translational research","url":"https://pubmed.ncbi.nlm.nih.gov/28670372","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"3536876","id":"PMC_3536876","title":"Cloning and mapping of the genetic determinants for microcin C7 production and immunity.","date":"1986","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/3536876","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23770038","id":"PMC_23770038","title":"Independent, parallel pathways to CXCL10 induction in HCV-infected hepatocytes.","date":"2013","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/23770038","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28623423","id":"PMC_28623423","title":"CXCL10 suppression of hem- and lymph-angiogenesis in inflamed corneas through MMP13.","date":"2017","source":"Angiogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/28623423","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21673103","id":"PMC_21673103","title":"Visfatin enhances CXCL8, CXCL10, and CCL20 production in human keratinocytes.","date":"2011","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/21673103","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15108349","id":"PMC_15108349","title":"Regulation of neuroinflammation: the role of CXCL10 in lymphocyte infiltration during autoimmune encephalomyelitis.","date":"2004","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15108349","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29122683","id":"PMC_29122683","title":"High CXCL10/IP-10 levels are a hallmark in the clinical evolution of the HIV infection.","date":"2017","source":"Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases","url":"https://pubmed.ncbi.nlm.nih.gov/29122683","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20153790","id":"PMC_20153790","title":"Th1 (CXCL10) and Th2 (CCL2) chemokine expression in patients with immune thrombocytopenia.","date":"2010","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/20153790","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30247799","id":"PMC_30247799","title":"C5aR1 interacts with TLR2 in osteoblasts and stimulates the osteoclast-inducing chemokine CXCL10.","date":"2018","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30247799","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36828808","id":"PMC_36828808","title":"MLKL signaling regulates macrophage polarization in acute pancreatitis through CXCL10.","date":"2023","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/36828808","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25693758","id":"PMC_25693758","title":"Serum levels of leptin and IP-10 in preeclampsia compared to controls.","date":"2015","source":"Archives of gynecology and obstetrics","url":"https://pubmed.ncbi.nlm.nih.gov/25693758","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31440475","id":"PMC_31440475","title":"Pathogen Evasion of Chemokine Response Through Suppression of CXCL10.","date":"2019","source":"Frontiers in cellular and infection microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/31440475","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31394157","id":"PMC_31394157","title":"Pulmonary fibroblasts-secreted CXCL10 polarizes alveolar macrophages under pro-inflammatory stimuli.","date":"2019","source":"Toxicology and applied pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/31394157","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34381047","id":"PMC_34381047","title":"Malaria parasites both repress host CXCL10 and use it as a cue for growth acceleration.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34381047","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38056897","id":"PMC_38056897","title":"CXCL10 and Nrf2-upregulated mesenchymal stem cells reinvigorate T lymphocytes for combating glioblastoma.","date":"2023","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/38056897","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9129152","id":"PMC_9129152","title":"Mob-1, a Ras target gene, is overexpressed in colorectal cancer.","date":"1997","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/9129152","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37487374","id":"PMC_37487374","title":"FABP4 in LSECs promotes CXCL10-mediated macrophage recruitment and M1 polarization during NAFLD progression.","date":"2023","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/37487374","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36483597","id":"PMC_36483597","title":"Role of CXCL10 in Spinal Cord Injury.","date":"2022","source":"International journal of medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36483597","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21270681","id":"PMC_21270681","title":"The chemokines CXCL10 and XCL1 recruit human annulus fibrosus cells.","date":"2012","source":"Spine","url":"https://pubmed.ncbi.nlm.nih.gov/21270681","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31666025","id":"PMC_31666025","title":"Accumulate evidence for IP-10 in diagnosing pulmonary tuberculosis.","date":"2019","source":"BMC infectious diseases","url":"https://pubmed.ncbi.nlm.nih.gov/31666025","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28065589","id":"PMC_28065589","title":"PERK and XBP1 differentially regulate CXCL10 and CCL2 production.","date":"2017","source":"Experimental eye research","url":"https://pubmed.ncbi.nlm.nih.gov/28065589","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23269790","id":"PMC_23269790","title":"T-cell infiltration correlates with CXCL10 expression in ganglia of cynomolgus macaques with reactivated simian varicella virus.","date":"2012","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/23269790","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16500735","id":"PMC_16500735","title":"Chemokine CXCL10 (IP-10) is sufficient to trigger an immune response to injected antigens in a mouse model.","date":"2005","source":"Vaccine","url":"https://pubmed.ncbi.nlm.nih.gov/16500735","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17407100","id":"PMC_17407100","title":"Hereditary complement C7 deficiency in nine families: subtotal C7 deficiency revisited.","date":"2007","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17407100","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35795684","id":"PMC_35795684","title":"A Teleost CXCL10 Is Both an Immunoregulator and an Antimicrobial.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35795684","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27764787","id":"PMC_27764787","title":"PDGFR-alpha inhibits melanoma growth via CXCL10/IP-10: a multi-omics approach.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27764787","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28906016","id":"PMC_28906016","title":"CXCL10 is upregulated in synovium and cartilage following articular fracture.","date":"2017","source":"Journal of orthopaedic research : official publication of the Orthopaedic Research Society","url":"https://pubmed.ncbi.nlm.nih.gov/28906016","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24025324","id":"PMC_24025324","title":"Elevated CXCL10 (IP-10) in bronchoalveolar lavage fluid is associated with acute cellular rejection after human lung transplantation.","date":"2014","source":"Transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/24025324","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33221386","id":"PMC_33221386","title":"CXCL5, CXCL8, and CXCL10 regulation by bacteria and mechanical forces in periodontium.","date":"2020","source":"Annals of anatomy = Anatomischer Anzeiger : official organ of the Anatomische Gesellschaft","url":"https://pubmed.ncbi.nlm.nih.gov/33221386","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27241258","id":"PMC_27241258","title":"Targeting the IFN-γ/CXCL10 pathway in lichen planus.","date":"2016","source":"Medical hypotheses","url":"https://pubmed.ncbi.nlm.nih.gov/27241258","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19450896","id":"PMC_19450896","title":"Induction of IP-10/CXCL10 secretion as an immunomodulatory effect of low-dose adjuvant interferon-alpha during treatment of melanoma.","date":"2009","source":"Immunobiology","url":"https://pubmed.ncbi.nlm.nih.gov/19450896","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32238853","id":"PMC_32238853","title":"Human Chorionic Gonadotropin modulates CXCL10 Expression through Histone Methylation in human decidua.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/32238853","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27500268","id":"PMC_27500268","title":"Detecting Renal Allograft Inflammation Using Quantitative Urine Metabolomics and CXCL10.","date":"2016","source":"Transplantation direct","url":"https://pubmed.ncbi.nlm.nih.gov/27500268","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28142122","id":"PMC_28142122","title":"COMMD7 promotes hepatocellular carcinoma through regulating CXCL10.","date":"2017","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/28142122","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26201916","id":"PMC_26201916","title":"CXC chemokine IP-10: a key actor in liver disease?","date":"2013","source":"Hepatology international","url":"https://pubmed.ncbi.nlm.nih.gov/26201916","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16240174","id":"PMC_16240174","title":"Alfalfa Mob 1-like genes are expressed in reproductive organs during meiosis and gametogenesis.","date":"2005","source":"Plant molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/16240174","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23502337","id":"PMC_23502337","title":"Differential expression of CXCL1, CXCL9, CXCL10 and CXCL12 chemokines in alopecia areata.","date":"2013","source":"Iranian journal of immunology : IJI","url":"https://pubmed.ncbi.nlm.nih.gov/23502337","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24247593","id":"PMC_24247593","title":"Histamine downregulates the Th1-associated chemokine IP-10 in monocytes and myeloid dendritic cells.","date":"2013","source":"International archives of allergy and immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24247593","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16825661","id":"PMC_16825661","title":"Role of IP-10/CXCL10 in the progression of pancreatitis-like injury in mice after murine retroviral infection.","date":"2006","source":"American journal of physiology. Gastrointestinal and liver physiology","url":"https://pubmed.ncbi.nlm.nih.gov/16825661","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19131211","id":"PMC_19131211","title":"IP-10 protects while MIP-2 promotes experimental anesthetic hapten - induced hepatitis.","date":"2009","source":"Journal of autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/19131211","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31232926","id":"PMC_31232926","title":"The role of CXCR3 and its ligands CXCL10 and CXCL11 in the pathogenesis of celiac disease.","date":"2019","source":"Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31232926","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39190494","id":"PMC_39190494","title":"CXCL9, CXCL10, and CCL19 synergistically recruit T lymphocytes to skin in lichen planus.","date":"2024","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/39190494","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24532643","id":"PMC_24532643","title":"Simvastatin attenuates rhinovirus-induced interferon and CXCL10 secretion from monocytic cells in vitro.","date":"2014","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/24532643","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7625765","id":"PMC_7625765","title":"Complement component C6 and C7 haplotypes associated with deficiencies of C6.","date":"1995","source":"Annals of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/7625765","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16226466","id":"PMC_16226466","title":"Elevated interleukin-12 and CXCL10 in subacute sclerosing panencephalitis.","date":"2005","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/16226466","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38335607","id":"PMC_38335607","title":"The interplay of Cxcl10+/Mmp14+ monocytes and Ccl3+ neutrophils proactively mediates silica-induced pulmonary fibrosis.","date":"2024","source":"Journal of hazardous materials","url":"https://pubmed.ncbi.nlm.nih.gov/38335607","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30718282","id":"PMC_30718282","title":"The antiviral protein viperin regulates chondrogenic differentiation via CXCL10 protein secretion.","date":"2019","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30718282","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31671580","id":"PMC_31671580","title":"Early Pregnancy Induces Expression of STAT1, OAS1 and CXCL10 in Ovine Spleen.","date":"2019","source":"Animals : an open access journal from MDPI","url":"https://pubmed.ncbi.nlm.nih.gov/31671580","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25309995","id":"PMC_25309995","title":"Critical Role of IP-10 on Reducing Experimental Corneal Neovascularization.","date":"2014","source":"Current eye research","url":"https://pubmed.ncbi.nlm.nih.gov/25309995","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29870118","id":"PMC_29870118","title":"Plasmacytoid dendritic cell heterogeneity is defined by CXCL10 expression following TLR7 stimulation.","date":"2018","source":"Immunology and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/29870118","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18560148","id":"PMC_18560148","title":"Structure of mouse IP-10, a chemokine.","date":"2008","source":"Acta crystallographica. Section D, Biological crystallography","url":"https://pubmed.ncbi.nlm.nih.gov/18560148","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32446778","id":"PMC_32446778","title":"The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system.","date":"2020","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/32446778","citation_count":936,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"3925348","id":"PMC_3925348","title":"Gamma-interferon transcriptionally regulates an early-response gene containing homology to platelet proteins.","date":"1985","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/3925348","citation_count":899,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15944327","id":"PMC_15944327","title":"Thymic stromal lymphopoietin expression is increased in asthmatic airways and correlates with expression of Th2-attracting chemokines and disease severity.","date":"2005","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/15944327","citation_count":681,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7566098","id":"PMC_7566098","title":"Initial assessment of human gene diversity and expression patterns based upon 83 million nucleotides of cDNA sequence.","date":"1995","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/7566098","citation_count":660,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21802343","id":"PMC_21802343","title":"CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications.","date":"2011","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/21802343","citation_count":648,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12782716","id":"PMC_12782716","title":"An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4.","date":"2003","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/12782716","citation_count":588,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7540647","id":"PMC_7540647","title":"Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo.","date":"1995","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/7540647","citation_count":571,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"31636098","id":"PMC_31636098","title":"Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade.","date":"2019","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/31636098","citation_count":569,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"24196705","id":"PMC_24196705","title":"HIV-1 evades innate immune recognition through specific cofactor recruitment.","date":"2013","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/24196705","citation_count":388,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12949249","id":"PMC_12949249","title":"Many chemokines including CCL20/MIP-3alpha display antimicrobial activity.","date":"2003","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/12949249","citation_count":379,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15919935","id":"PMC_15919935","title":"Cytokine responses in severe acute respiratory syndrome coronavirus-infected macrophages in vitro: possible relevance to pathogenesis.","date":"2005","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/15919935","citation_count":347,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15315758","id":"PMC_15315758","title":"One nucleotide in a kappaB site can determine cofactor specificity for NF-kappaB dimers.","date":"2004","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/15315758","citation_count":330,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12016104","id":"PMC_12016104","title":"Increased expression of the chemokine receptor CXCR3 and its ligand CXCL10 in peripheral airways of smokers with chronic obstructive pulmonary disease.","date":"2002","source":"American journal of respiratory and critical care medicine","url":"https://pubmed.ncbi.nlm.nih.gov/12016104","citation_count":279,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9462486","id":"PMC_9462486","title":"The immunobiology of interferon-gamma inducible protein 10 kD (IP-10): a novel, pleiotropic member of the C-X-C chemokine superfamily.","date":"1997","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/9462486","citation_count":273,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11110785","id":"PMC_11110785","title":"The ligands of CXC chemokine receptor 3, I-TAC, Mig, and IP10, are natural antagonists for CCR3.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11110785","citation_count":249,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23144331","id":"PMC_23144331","title":"CXCL10-CXCR3 enhances the development of neutrophil-mediated fulminant lung injury of viral and nonviral origin.","date":"2012","source":"American journal of respiratory and critical care medicine","url":"https://pubmed.ncbi.nlm.nih.gov/23144331","citation_count":238,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11390394","id":"PMC_11390394","title":"Kinetic investigation of chemokine truncation by CD26/dipeptidyl peptidase IV reveals a striking selectivity within the chemokine family.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11390394","citation_count":227,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15879427","id":"PMC_15879427","title":"The CXCL10/CXCR3 axis mediates human lung mast cell migration to asthmatic airway smooth muscle.","date":"2005","source":"American journal of respiratory and critical care medicine","url":"https://pubmed.ncbi.nlm.nih.gov/15879427","citation_count":225,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33121429","id":"PMC_33121429","title":"IP-10 and MCP-1 as biomarkers associated with disease severity of COVID-19.","date":"2020","source":"Molecular medicine (Cambridge, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/33121429","citation_count":220,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"27490802","id":"PMC_27490802","title":"CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer.","date":"2016","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/27490802","citation_count":219,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15150261","id":"PMC_15150261","title":"Intracellular domains of CXCR3 that mediate CXCL9, CXCL10, and CXCL11 function.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15150261","citation_count":217,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10201901","id":"PMC_10201901","title":"Chemokine receptor responses on T cells are achieved through regulation of both receptor expression and signaling.","date":"1999","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/10201901","citation_count":213,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32816891","id":"PMC_32816891","title":"Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma.","date":"2020","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/32816891","citation_count":203,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26406121","id":"PMC_26406121","title":"Mixed lineage kinase 3 mediates release of C-X-C motif ligand 10-bearing chemotactic extracellular vesicles from lipotoxic hepatocytes.","date":"2015","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/26406121","citation_count":202,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16733654","id":"PMC_16733654","title":"Chemokine expression by astrocytes plays a role in microglia/macrophage activation and subsequent neurodegeneration in secondary progressive multiple sclerosis.","date":"2006","source":"Acta neuropathologica","url":"https://pubmed.ncbi.nlm.nih.gov/16733654","citation_count":194,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12384933","id":"PMC_12384933","title":"Involvement of the interferon-gamma-induced T cell-attracting chemokines, interferon-gamma-inducible 10-kd protein (CXCL10) and monokine induced by interferon-gamma (CXCL9), in the salivary gland lesions of patients with Sjögren's syndrome.","date":"2002","source":"Arthritis and rheumatism","url":"https://pubmed.ncbi.nlm.nih.gov/12384933","citation_count":185,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16697675","id":"PMC_16697675","title":"HIV tat and neurotoxicity.","date":"2006","source":"Microbes and infection","url":"https://pubmed.ncbi.nlm.nih.gov/16697675","citation_count":184,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":51120,"output_tokens":7941,"usd":0.136238},"stage2":{"model":"claude-opus-4-6","input_tokens":11697,"output_tokens":4103,"usd":0.24159},"total_usd":0.831609,"stage1_batch_id":"msgbatch_011kfMfE81o6CTcyhVUqumuW","stage2_batch_id":"msgbatch_01DTputS6WNkH745x1nVSoBo","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":66231,"output_tokens":10770,"usd":0.180121},"round2_rules_fired":"R2,R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":15068,"output_tokens":4284,"usd":0.27366}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1997,\n      \"finding\": \"CXCL10 (IP-10) and Mig share the receptor CXCR3 on activated T cells, demonstrated by reciprocal desensitization experiments; CXCL10 acts as a chemoattractant for stimulated (but not resting) T cells and inhibits neovascularization and hematopoietic progenitor cells.\",\n      \"method\": \"Recombinant protein chemotaxis assays, cross-desensitization on activated T cells, in vitro and in vivo functional assays\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal in vitro and in vivo assays, foundational receptor identification paper, >650 citations\",\n      \"pmids\": [\"9060447\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"CXCL10 oligomerization is required for presentation on endothelial cells and in vivo T-cell recruitment; a monomeric IP-10 mutant retains in vitro chemotactic activity but fails to recruit CD8+ T cells into airways in vivo and cannot bind to or mediate transendothelial migration on endothelial cells.\",\n      \"method\": \"Monomeric CXCL10 mutant, intratracheal instillation in mice, molecular imaging, in vitro endothelial cell binding and transendothelial migration assays\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution with defined mutants, in vitro + in vivo orthogonal methods, strong mechanistic conclusion\",\n      \"pmids\": [\"17082614\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Crystal structure of mouse IP-10 reveals a novel tetrameric association in which two conventional CXC dimers associate through N-terminal regions to form a 12-stranded elongated beta-sheet; heparin-binding and receptor-binding residues were mapped on the tetramer surface with two heparin-binding sites at each dimer interface.\",\n      \"method\": \"X-ray crystallography with heparin- and receptor-binding residue mapping\",\n      \"journal\": \"Acta crystallographica. Section D, Biological crystallography\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure with functional residue mapping\",\n      \"pmids\": [\"18560148\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CXCL10 impairs beta-cell viability and insulin secretion through TLR4 signaling (not CXCR3), inducing sustained activation of Akt, JNK, and cleavage of PAK-2 to switch Akt signals from proliferation to apoptosis.\",\n      \"method\": \"Human islet treatment with recombinant CXCL10, TLR4 receptor identification (CXCR3-independent), western blot for Akt/JNK/PAK-2, cell viability and insulin secretion assays\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods in primary human islets, receptor specificity established, novel non-canonical receptor identified\",\n      \"pmids\": [\"19187771\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CXCL10 inhibits endothelial cell proliferation independently of CXCR3; this anti-proliferative effect correlates with glycosaminoglycan (heparin) binding affinity rather than CXCR3 binding, as shown by CXCR3-knockout endothelial cells, CXCR3-negative human endothelial cells, neutralizing CXCR3 antibodies, and a panel of CXCL10 mutants.\",\n      \"method\": \"CXCR3-knockout mouse endothelial cells, FACS for CXCR3 expression, neutralizing antibodies, CXCL10 mutant panel with defined GAG- vs CXCR3-binding properties, in vitro proliferation assay\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — four independent lines of evidence with genetic knockout, antibody blockade, and structure-function mutant analysis\",\n      \"pmids\": [\"20856926\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"CXCL10 acting via CXCR3-A upregulates IFN-gamma and downregulates IL-4/IL-5/IL-13 in human CD4+ T cells, promoting Th1 differentiation; these effects involve upregulation of T-bet and downregulation of GATA-3, and operate through distinct signaling pathways from CXCL4/CXCR3-B which drives opposite Th2 effects.\",\n      \"method\": \"Antigen-specific human CD4+ T-cell lines, quantitative RT-PCR, flow cytometry, ELISA, anti-CXCR3 antibody neutralization, IL-5 and IL-13 promoter reporter assays\",\n      \"journal\": \"The Journal of allergy and clinical immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods, specific receptor isoform discrimination, transcription factor target identified\",\n      \"pmids\": [\"16337473\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Macrophages drive B-cell differentiation into plasma cells through secreted CXCL10/IP-10; CXCL10 production by macrophages is induced by B-cell-derived IL-6 via STAT3 phosphorylation, and CXCL10 in turn amplifies IL-6 production by B cells, sustaining STAT3 signals for plasma cell differentiation. IP-10-deficient mice show decreased plasma cell frequency and lower antibody titers.\",\n      \"method\": \"Human macrophage/B-cell co-culture, CXCL10 neutralization, VCAM-1 contact studies, IP-10-deficient mouse immunization model, STAT3 pathway analysis\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vitro mechanistic dissection plus in vivo genetic KO confirmation, multiple orthogonal approaches\",\n      \"pmids\": [\"22987802\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CXCL10/CXCR3 signaling promotes fibroblast-like synoviocyte (FLS) invasion by stimulating MMP-1 production, intracellular calcium influx, and actin cytoskeleton reorganization/lamellipodia formation; CXCR3 blockade reduces invasiveness by up to 77% in rat and human RA FLS.\",\n      \"method\": \"Matrigel invasion assay, anti-CXCR3 antibody and small-molecule inhibitor (AMG487), MMP-1-3 ELISA, intracellular calcium imaging, actin cytoskeleton morphology\",\n      \"journal\": \"Arthritis and rheumatism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal functional readouts, both rat and human RA FLS, genetic/pharmacologic CXCR3 inhibition\",\n      \"pmids\": [\"21811993\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"MRP8/MRP14 (DAMPs) stimulate CXCL10/IP-10 production in monocytes/macrophages through TLR4 and TRIF (not MyD88), requiring cooperative activation of NF-κB and IRF3 transcription factors; CXCL10 produced via this pathway then mediates chemotaxis of CXCR3+ cells.\",\n      \"method\": \"THP-1 monocyte stimulation, TLR4/TRIF/MyD88 pathway dissection with inhibitors and siRNA, NF-κB and IRF3 activation assays, in vivo mouse trauma/hemorrhagic shock model with neutralizing anti-MRP8 antibody\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — receptor and adaptor pathway dissected with multiple inhibitors, in vitro and in vivo confirmation\",\n      \"pmids\": [\"25342131\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"CXCL10 induces robust IL-12 and IL-23 production from IFN-γ-primed human monocytes through CXCR3 engagement and downstream IκB kinase and p38 MAPK signaling pathways; anti-CXCL10 antibody treatment in an innate murine colitis model suppressed local myeloid-derived inflammatory cytokines and reduced intestinal tissue damage.\",\n      \"method\": \"Human monocyte stimulation with recombinant CXCL10, CXCR3 blocking antibody, IKK and p38 MAPK inhibitors, cytokine ELISA, in vivo colitis model with anti-CXCL10 antibody treatment\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — receptor and signaling pathway defined with pharmacologic inhibitors, in vitro and in vivo validation\",\n      \"pmids\": [\"28899907\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CXCL10 gene repression in IPF lung fibroblasts involves histone deacetylation and histone H3 hypermethylation at the CXCL10 promoter, mediated by decreased recruitment of histone acetyltransferases, increased HDAC-containing repressor complexes, and histone methyltransferases G9a and SUV39H1, leading to reduced transcription factor binding; HDAC or G9a inhibitors restore CXCL10 expression.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP), nuclear run-on, HDAC and G9a inhibitor treatment of IPF fibroblasts, epigenetic complex analysis\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — ChIP with multiple histone marks, nuclear run-on, pharmacologic rescue, mechanistically rigorous\",\n      \"pmids\": [\"20404089\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"EZH2 (H3K27 methylation) and G9a (H3K9 methylation) physically interact and function interdependently at the CXCL10 promoter in IPF fibroblasts; knockdown of either enzyme reduces both H3K27me3 and H3K9me3 marks and restores CXCL10 expression; TGF-β1 drives this dual repressive mechanism.\",\n      \"method\": \"ChIP, Re-ChIP, proximity ligation assay, EZH2/G9a siRNA knockdown and pharmacologic inhibition, TGF-β1 stimulation of normal fibroblasts\",\n      \"journal\": \"American journal of respiratory cell and molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — Re-ChIP and PLA for physical interaction, genetic knockdown of both enzymes, replicated in disease and TGF-β1 model\",\n      \"pmids\": [\"29053336\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"IP-10/CXCL10-deficient mice exhibit increased pulmonary fibrosis after bleomycin exposure with dramatically increased fibroblast accumulation; IP-10 inhibits fibroblast migration but not proliferation in response to lung-derived chemoattractant activity; transgenic IP-10-overexpressing mice are protected from bleomycin-induced mortality with decreased fibroblast accumulation.\",\n      \"method\": \"CXCL10-knockout mice, IP-10-transgenic mice, bleomycin pulmonary fibrosis model, fibroblast chemotaxis and proliferation assays\",\n      \"journal\": \"American journal of respiratory cell and molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — both loss-of-function (KO) and gain-of-function (transgenic) genetic models with defined cellular phenotype, in vitro mechanistic assay\",\n      \"pmids\": [\"15205180\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"IP-10/CXCL10 exerts hepatoprotective effects in acetaminophen-induced acute liver injury by upregulating CXCR2 expression on hepatocytes, which mediates a CXCR2-dependent hepatocyte proliferative response; neutralization of CXCR2 abolishes IP-10's hepatoprotective effect.\",\n      \"method\": \"Recombinant IP-10 administration in mice, CXCR2 neutralization, histology, ALT assay, hepatocyte culture proliferation assay\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo and in vitro with antibody blockade, but single lab study\",\n      \"pmids\": [\"11739529\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"CMV-induced CXCL10 production in microglia requires p38 MAP kinase phosphorylation (not secondary protein synthesis); IL-10 suppresses this CXCL10 production by decreasing NF-κB activation; CMV-encoded viral IL-10 (cmvIL-10/UL111a) from infected astrocytes also inhibits CXCL10 production via the IL-10 receptor.\",\n      \"method\": \"Primary human microglial cell CMV infection, p38 inhibitors, cycloheximide, IL-10/IL-4/TGF-β cytokine treatment, NF-κB activation assays, conditioned medium experiments with IL-10R blocking\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple signaling pathway inhibitors tested, novel viral immune evasion mechanism identified, but single lab\",\n      \"pmids\": [\"12663757\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"CXCL10 induction in hepatocytes during early HCV infection occurs through independent parallel TLR3 and RIG-I pathways, and is independent of hepatocyte-derived type I and type III IFNs; non-parenchymal cell-derived IFNs contribute to CXCL10 induction in primary human hepatocyte cultures.\",\n      \"method\": \"HuH7 cells with functional/non-functional TLR3 and RIG-I, type I/III IFN neutralization, non-parenchymal cell immunodepletion, immunofluorescence correlation of HCV Core and CXCL10 protein\",\n      \"journal\": \"Journal of hepatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic/functional pathway dissection with multiple cell systems and immunodepletion, moderate evidence\",\n      \"pmids\": [\"23770038\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"EGFR activation (triggered by respiratory viruses including influenza, rhinovirus, and RSV) suppresses IRF1-dependent CXCL10 production in airway epithelial cells; EGFR inhibition augments IRF1 and CXCL10 levels during viral infection.\",\n      \"method\": \"Airway epithelial cell infection with three respiratory viruses, EGFR inhibitors, IRF1 and CXCL10 measurement by western blot and ELISA\",\n      \"journal\": \"American journal of physiology. Lung cellular and molecular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacologic EGFR inhibition across multiple virus types, IRF1 pathway identified, single lab\",\n      \"pmids\": [\"24838750\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Leishmania major virulence factor GP63 (a protease) cleaves CXCL10 after amino acid A81 at the base of the C-terminal alpha-helix, inactivating its T-cell chemotactic function (cleaved CXCL10 cannot signal through CXCR3); this cleavage is specific to CXCR3 ligands and is produced by both extracellular promastigotes and intracellular amastigotes.\",\n      \"method\": \"Recombinant GP63 protease cleavage assay, mass spectrometry for cleavage site identification, CXCR3 signaling assay, T-cell chemotaxis assay with cleaved vs. intact CXCL10\",\n      \"journal\": \"Frontiers in cellular and infection microbiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — cleavage site identified by MS, functional consequence (CXCR3 signaling, T cell chemotaxis) validated, substrate specificity defined\",\n      \"pmids\": [\"31440475\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"An IP-10-derived 21-amino-acid peptide (IP-10p) spanning the C-terminal alpha-helical domain (residues 77-98) inhibits VEGF-induced endothelial motility and tube formation via CXCR3-mediated increase in cAMP, PKA activation inhibiting cell migration, and inhibition of VEGF-mediated m-calpain activation; CXCR3-neutralizing antibody blocks these effects.\",\n      \"method\": \"Recombinant peptide treatment of endothelial cells, Matrigel plug assay in vivo, cAMP measurement, PKA activity, m-calpain assay, CXCR3-neutralizing antibody blockade\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple signaling endpoints measured, in vitro and in vivo, receptor specificity confirmed\",\n      \"pmids\": [\"22815829\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"CXCL10 promotes epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma cells via MMP-2 as a downstream effector; CXCL10 overexpression enhances migration/invasion in vitro and in vivo, and silencing CXCL10 inhibits metastasis.\",\n      \"method\": \"CXCL10 overexpression and siRNA silencing in HCC cells, microarray analysis identifying MMP-2 as downstream target, in vitro invasion/migration assays, in vivo metastasis model\",\n      \"journal\": \"American journal of translational research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — gain and loss of function with in vitro and in vivo validation, MMP-2 pathway identified by microarray, single lab\",\n      \"pmids\": [\"28670372\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"CXCL10 suppresses corneal hem- and lymph-angiogenesis by downregulating angiogenic factors including VEGFa, VEGFc, and MMP-13; inhibition of MMP-13 (but not TIMPs) attenuates corneal neovascularization independent of CXCL10 expression, placing MMP-13 downstream of CXCL10.\",\n      \"method\": \"AAV9-driven corneal CXCL10 overexpression, CXCL10/CXCR3 neutralization, MMP-13 inhibition, VEGF expression analysis in vivo\",\n      \"journal\": \"Angiogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic overexpression, neutralization, and downstream inhibitor experiments, in vivo model\",\n      \"pmids\": [\"28623423\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"CXCL10 secretion from TNF-α/IL-1β-activated pulmonary fibroblasts promotes M1 polarization of alveolar macrophages; upstream fibroblast signaling involves STAT3, FAK, GSK3αβ, and PKCδ phosphorylation; CXCL10 neutralization abolishes conditioned-medium-induced M1 polarization.\",\n      \"method\": \"MRC-5 fibroblast-macrophage conditioned medium system, CXCL10 neutralizing antibody, STAT3/FAK/GSK3αβ/PKCδ inhibitors, iNOS/arginase/CD86/CD206 marker analysis by RT-PCR and flow cytometry\",\n      \"journal\": \"Toxicology and applied pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — signaling pathway dissected with multiple inhibitors, functional readout confirmed by neutralization\",\n      \"pmids\": [\"31394157\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Viperin controls chondrogenic differentiation by regulating secretion of CXCL10, which in turn influences TGF-β/SMAD2/3 activity; disturbances in this viperin-CXCL10-TGF-β/SMAD2/3 axis were observed in cartilage-hair hypoplasia (CHH) chondrocytic cells.\",\n      \"method\": \"Viperin siRNA silencing and overexpression in chondrocytic cells, ELISA, label-free MS proteomics, SMAD2/3 phosphorylation assays, CHH patient-derived cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — gain/loss of function with proteomics and signaling pathway validation, disease-relevant cells included\",\n      \"pmids\": [\"30718282\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Human chorionic gonadotropin (hCG) inhibits CXCL10 expression in decidual stromal cells by inducing H3K27me3 histone methylation at Region 4 of the CXCL10 promoter via EZH2 (a PRC2 complex member), thereby suppressing CD8+ T-cell recruitment to the maternal-fetal interface.\",\n      \"method\": \"ChIP for H3K27me3 at CXCL10 promoter regions, EZH2 inhibition, decidual stromal cell culture, hCG treatment, T-cell migration assay\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP maps specific promoter region, EZH2 identified as writer, functional consequence (T-cell recruitment) measured\",\n      \"pmids\": [\"32238853\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"OPTN-dependent mitophagy induced by PEM/CDDP plus MEK inhibitor triggers CXCL10 secretion by cancer cells in a mitochondrial DNA- and TLR9-dependent manner, which recruits CD8+ T cells and sensitizes tumors to immune checkpoint inhibitors.\",\n      \"method\": \"Drug combination screening, OPTN/TLR9 genetic inhibition, mitophagy assays, CXCL10 ELISA, CD8+ T-cell recruitment in vivo, human NSCLC expression correlation\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic validation of OPTN-TLR9-CXCL10 axis with in vivo confirmation, multiple orthogonal approaches, single lab\",\n      \"pmids\": [\"35051357\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"MLKL (mixed-lineage kinase domain-like protein) in pancreatic acinar cells promotes M1 macrophage polarization through CXCL10 secretion; Mlkl knockout reduces CXCL10 secretion and M1 polarization; in vitro CXCL10 neutralization impairs pro-M1 activity, and in vivo CXCL10 neutralization reduces M1 polarization and acute pancreatitis severity.\",\n      \"method\": \"Mlkl-/- and Ripk3-/- mice, cerulein/LPS AP model, CXCL10 neutralizing antibody (in vitro and in vivo), macrophage polarization markers, conditioned medium experiments\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockout plus antibody neutralization, in vitro and in vivo, defines MLKL-CXCL10-macrophage axis\",\n      \"pmids\": [\"36828808\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"P. falciparum inhibits CXCL10 synthesis in monocytes by delivering RNA cargo that triggers RIG-I, leading to HuR binding to an AU-rich domain in the CXCL10 3'UTR, thereby suppressing ribosome association with CXCL10 transcripts; high CXCL10 conversely acts as a cue for parasite growth acceleration.\",\n      \"method\": \"Monocyte RNA transfection, RIG-I pathway analysis, HuR-CXCL10 3'UTR binding assay, polysome profiling for ribosome association\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic RNA-level regulation identified with RIG-I, HuR, and 3'UTR experiments, novel post-transcriptional mechanism\",\n      \"pmids\": [\"34381047\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"C5aR1 interacts physically with TLR2 in osteoblasts (shown by co-immunoprecipitation); C5a stimulation activates p38 MAPK signaling and induces CXCL10 production as an osteoclastogenic factor through convergence of C5aR1 and TLR2 signaling on p38 MAPK.\",\n      \"method\": \"Whole-genome microarray, co-immunoprecipitation of C5aR1 and TLR2, p38 MAPK activation assays, CXCL10 ELISA\",\n      \"journal\": \"Journal of cellular and molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — single Co-IP for receptor interaction, but microarray plus signaling assays provide moderate mechanistic support\",\n      \"pmids\": [\"30247799\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Heparanase expression in myeloma cells is associated with decreased CXCL10 levels; recombinant CXCL10 attenuates myeloma cell proliferation and endothelial cell proliferation (anti-angiogenic); CXCL10-overexpressing myeloma xenografts show markedly reduced tumor growth and CXCL10-Ig fusion protein treatment attenuates tumor growth in vivo.\",\n      \"method\": \"Inducible heparanase Tet-on system, soft-agar colony assay, xenograft tumor model, recombinant CXCL10 and CXCL10-Ig fusion protein treatment, proliferation assays\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — inducible system, in vitro and in vivo validation, anti-proliferative mechanism confirmed\",\n      \"pmids\": [\"24699306\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"PERK pathway (via NF-κB RelA and STAT3 phosphorylation) positively regulates CXCL10 expression during ER stress in photoreceptors, while XBP1 (IRE1α pathway) negatively regulates CXCL10 expression; PERK knockdown attenuates CXCL10, while XBP1 knockdown enhances CXCL10.\",\n      \"method\": \"siRNA knockdown of PERK and XBP1, ER stress induction with thapsigargin, NF-κB and STAT3 pathway inhibition, RT-PCR and ELISA\",\n      \"journal\": \"Experimental eye research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockdown of two ER stress pathway branches with defined signaling readouts, validated in multiple stress conditions\",\n      \"pmids\": [\"28065589\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CXCL10 is an IFN-γ-inducible CXC chemokine that signals primarily through its high-affinity G protein-coupled receptor CXCR3 to recruit activated Th1 lymphocytes and NK cells, with receptor-independent anti-proliferative effects on endothelial cells mediated through glycosaminoglycan binding; it forms functional oligomers required for endothelial cell presentation and in vivo T-cell recruitment, undergoes epigenetic repression in fibrotic disease through cooperative EZH2- and G9a-mediated histone methylation, activates multiple downstream pathways (Akt, JNK, p38 MAPK, NF-κB, IRF3) depending on cell context, can signal non-canonically through TLR4 in pancreatic beta cells, promotes plasma cell differentiation via an IL-6/STAT3 feedback loop with macrophages, and is subject to post-translational cleavage and inactivation by pathogen-encoded proteases.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1985,\n      \"finding\": \"CXCL10 (IP-10) was identified as an IFN-γ-inducible early-response gene encoding a protein with homology to platelet factor-4 and β-thromboglobulin (CXC chemokine family); its mRNA is induced within 30 min of IFN-γ treatment with >30-fold accumulation, and increased transcription contributes to this accumulation.\",\n      \"method\": \"Molecular cloning, Northern blot, nuclear run-on transcription assay\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — original cloning with multiple orthogonal methods; foundational, highly cited\",\n      \"pmids\": [\"3925348\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"CRG-2, the mouse homologue of human IP-10/CXCL10, encodes a 98-amino-acid secreted protein (21-residue signal peptide) of the PF4 family; its mRNA is induced by IFN-α, IFN-β, and IFN-γ as well as LPS, peaks at 3–6 h after IFN-γ, and accumulation is not blocked by cycloheximide (primary response gene).\",\n      \"method\": \"cDNA library screening, differential hybridization, Northern blot, cycloheximide experiments, 5′-flanking region isolation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution-level molecular characterization; foundational paper with multiple orthogonal methods\",\n      \"pmids\": [\"2118520\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"CXCL10 (IP-10) is a potent inhibitor of angiogenesis in vivo; it profoundly inhibited bFGF-induced neovascularization in a Matrigel model and suppressed endothelial cell differentiation into tubular capillary structures in vitro, without affecting endothelial cell growth, attachment, or migration.\",\n      \"method\": \"In vivo Matrigel plug assay (athymic mice), in vitro tube formation assay, endothelial cell growth/attachment/migration assays\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple in vitro and in vivo assays; highly cited foundational study\",\n      \"pmids\": [\"7540647\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"CXCL10 (IP-10) and CXCL9 (Mig) share the receptor CXCR3; both chemokines are chemotactic specifically for activated (but not resting) T cells, show reciprocal desensitization on activated T cells, inhibit neovascularization, inhibit hematopoietic progenitor cells, and have anti-tumor effects, but lack neutrophil chemotactic activity.\",\n      \"method\": \"Recombinant protein chemotaxis assays, desensitization assays, receptor-sharing functional studies\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple functional assays with recombinant proteins; highly cited review synthesizing original experimental data\",\n      \"pmids\": [\"9060447\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"CXCL10 receptor CXCR3 is expressed by human mesangial cells; CXCL10 binding to CXCR3 on mesangial cells induces intracellular Ca²⁺ influx and directly stimulates mesangial cell proliferation.\",\n      \"method\": \"Flow cytometry, intracellular Ca²⁺ measurement, cell proliferation assay\",\n      \"journal\": \"Journal of the American Society of Nephrology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional receptor assays with calcium flux and proliferation readout in primary cells\",\n      \"pmids\": [\"10589690\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Murine Crg-2 (mouse IP-10/CXCL10) expressed via recombinant vaccinia virus enhances NK cell cytolytic activity, increases mononuclear cell infiltration in liver, and is required along with IFN-α/β and IFN-γ for controlling viral replication in athymic nude mice, establishing an antiviral role in vivo.\",\n      \"method\": \"Recombinant vaccinia virus expression, in vivo viral challenge model, NK cell depletion with neutralizing antibodies, cytolytic activity assays\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo epistasis via antibody depletion with defined survival and cellular phenotype readouts\",\n      \"pmids\": [\"9882354\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"CXCL10 (IP-10), together with CXCL9 and CXCL11, acts as a natural antagonist for the Th2 chemokine receptor CCR3; it competes for eotaxin binding to CCR3-expressing cells and inhibits CCR3-mediated migration and Ca²⁺ signaling without inducing CCR3 internalization (pure antagonist).\",\n      \"method\": \"Radioligand competition binding assay, chemotaxis assay, Ca²⁺ mobilization assay, receptor internalization assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple orthogonal biochemical assays; highly cited mechanistic study\",\n      \"pmids\": [\"11110785\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"CD26/dipeptidyl peptidase IV cleaves CXCL10 (and CXCL9, CXCL11, CXCL12, CCL22) with striking selectivity; kinetic analysis shows CXCL10 is a substrate for N-terminal truncation by CD26/DPPIV, a mechanism that modulates chemokine activity in vivo.\",\n      \"method\": \"Steady-state kinetics (Km, kcat), mass spectrometry-based truncation analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — rigorous enzyme kinetics with defined substrates; highly cited\",\n      \"pmids\": [\"11390394\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"CXCL10 (IP-10) has a hepatoprotective/regenerative effect during acute liver injury; its therapeutic effect is mediated through upregulation of CXCR2 on hepatocytes, with CXCR2 neutralization abrogating the effect. CXCL10 treatment of cultured hepatocytes stimulates a CXCR2-dependent proliferative response.\",\n      \"method\": \"Mouse APAP-injury model, rIP-10 administration, CXCR2 neutralizing antibody, hepatocyte proliferation assay in vitro\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function (neutralizing antibody) with defined cellular and biochemical phenotype; in vitro confirmation\",\n      \"pmids\": [\"11739529\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"CXCL10 is constitutively expressed in basal colonic crypts and upregulated during colitis; recombinant CXCL10 administration inhibits intestinal epithelial cell proliferation, while CXCL10 neutralization promotes crypt cell survival and protects from epithelial ulceration independent of altered immune cell infiltration.\",\n      \"method\": \"DSS colitis mouse model, anti-CXCL10 neutralizing antibody, recombinant CXCL10 administration, histology\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — loss- and gain-of-function in vivo with defined epithelial phenotype\",\n      \"pmids\": [\"12555665\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"CXCL10 is induced in CMV-infected primary microglia through p38 MAP kinase phosphorylation (not requiring secondary protein synthesis); IL-10 suppresses CMV-induced CXCL10 by decreasing NF-κB activation (not p38 phosphorylation); viral cmvIL-10 (UL111a, spliced form) from CMV-infected astrocytes inhibits microglial CXCL10 production through the IL-10 receptor.\",\n      \"method\": \"Primary microglia infection, p38 inhibitor, cycloheximide treatment, NF-κB reporter assay, conditioned medium experiments, IL-10R blockade\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple pathway inhibitors with defined signaling readouts\",\n      \"pmids\": [\"12663757\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"An alternatively spliced variant of CXCR3, termed CXCR3-B, mediates the angiostatic activity of CXCL10 (as well as CXCL9 and CXCL11) on endothelial cells; CXCR3-B overexpression dramatically reduces DNA synthesis and upregulates apoptosis via distinct signal transduction pathways from CXCR3-A, and also acts as functional receptor for CXCL4/PF4.\",\n      \"method\": \"Alternative splicing identification, receptor transfection (CXCR3-A vs CXCR3-B), binding assays, DNA synthesis assay, apoptosis assay, signal transduction analysis, immunohistochemistry on tumor tissue\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — receptor reconstitution with mutagenesis/splice variants plus multiple functional readouts; highly cited\",\n      \"pmids\": [\"12782716\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"CXCR3 intracellular domains differentially mediate CXCL9, CXCL10, and CXCL11 signaling: the carboxyl-terminal domain and β-arrestin1 are predominantly required for CXCL9- and CXCL10-induced internalization, while the third intracellular loop is predominantly required by CXCL11; chemotaxis and Ca²⁺ mobilization by all three ligands require both the CXCR3 C-terminus and the DRY sequence in TM3.\",\n      \"method\": \"Domain deletion/mutation analysis, β-arrestin1 dominant-negative, internalization assay, Ca²⁺ mobilization, chemotaxis assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — systematic mutagenesis with multiple functional readouts; highly cited mechanistic study\",\n      \"pmids\": [\"15150261\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"EGFR-activated signaling (via NADPH oxidase/metalloproteinase pathway) during respiratory virus infection suppresses IRF1-dependent CXCL10 production in airway epithelial cells; EGFR inhibition augments IRF1 and CXCL10 levels, while EGFR activation suppresses them.\",\n      \"method\": \"Influenza/rhinovirus/RSV infection of airway epithelial cells, EGFR inhibitors, IRF1 knockdown, CXCL10 ELISA and qPCR\",\n      \"journal\": \"American journal of physiology. Lung cellular and molecular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological and genetic inhibition with defined signaling mechanism and protein readouts\",\n      \"pmids\": [\"24838750\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"NF-κB κB site sequence determines cofactor specificity; for CXCL10 and other genes with two κB sites, both sites are required for activity, and the sequence of each κB site determines which coactivators productively interact with the bound NF-κB dimer rather than simply which dimer binds.\",\n      \"method\": \"Lentivirus-based κB site implantation, κB site swapping between genes, NF-κB dimer specificity assays\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution and mutagenesis of regulatory elements with CXCL10 as a direct experimental model; highly cited\",\n      \"pmids\": [\"15315758\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"IP-10/CXCL10 attenuates bleomycin-induced pulmonary fibrosis by inhibiting fibroblast migration (chemoattractant activity) but not fibroblast proliferation; IP-10-deficient mice show dramatically increased fibroblast accumulation and fibrosis after bleomycin, while IP-10-overexpressing transgenic mice are protected.\",\n      \"method\": \"IP-10 knockout mice, IP-10 transgenic overexpression mice, bleomycin pulmonary fibrosis model, fibroblast chemotaxis/proliferation assays in vitro\",\n      \"journal\": \"American journal of respiratory cell and molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal genetic (KO + transgenic) in vivo models with mechanistic in vitro follow-up\",\n      \"pmids\": [\"15205180\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"CXCL10 via CXCR3 upregulates IFN-γ and T-bet expression while downregulating IL-4, IL-5, IL-13, and GATA-3 in CD4+ T cells, promoting Th1 differentiation; these effects are mediated through distinct signal transduction pathways compared with CXCL4/CXCR3-B, which has opposite effects promoting Th2 cytokines.\",\n      \"method\": \"Antigen-specific human CD4+ T-cell lines, anti-CXCR3 neutralizing antibody, qRT-PCR, flow cytometry, ELISA, IL-5/IL-13 promoter activation assay\",\n      \"journal\": \"The Journal of allergy and clinical immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (signaling, transcription factor, cytokine) in primary human T cells\",\n      \"pmids\": [\"16337473\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"CXCL10 produced preferentially by asthmatic airway smooth muscle mediates migration of human lung mast cells to airway smooth muscle predominantly through CXCR3 activation; CXCR3 is expressed on 100% of mast cells within the airway smooth muscle bundle in asthma.\",\n      \"method\": \"Immunohistochemistry of bronchial biopsies, ex vivo airway smooth muscle supernatants, mast cell chemotaxis assay, ELISA\",\n      \"journal\": \"American journal of respiratory and critical care medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional chemotaxis assay with tissue-derived supernatants plus receptor expression in primary tissue\",\n      \"pmids\": [\"15879427\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Oligomerization of CXCL10 is required for its presentation on endothelial cells and for in vivo T cell recruitment; a monomeric CXCL10 mutant retains in vitro chemotaxis activity but fails to recruit CD8+ T cells into mouse airways after intratracheal instillation and cannot bind to or enable transendothelial chemotaxis on endothelial cells, independent of reduced CXCR3 or heparin binding.\",\n      \"method\": \"Monomeric CXCL10 mutant, in vitro chemotaxis assay, intratracheal instillation in mice, molecular imaging, endothelial cell binding assay, transendothelial migration assay\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — defined mutant protein with multiple orthogonal in vitro and in vivo functional assays\",\n      \"pmids\": [\"17082614\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Crystal structure of mouse IP-10/CXCL10 reveals a novel tetrameric association where two conventional CXC dimers associate through N-terminal regions forming a 12-stranded elongated β-sheet (~90 Å); two heparin-binding sites are located at the interface of each β-sheet dimer; this tetramer structure differs from previously described IP-10, PF4 and NAP-2 tetramers and supports higher-order oligomer formation.\",\n      \"method\": \"X-ray crystallography, surface mapping of heparin- and receptor-binding residues\",\n      \"journal\": \"Acta crystallographica. Section D, Biological crystallography\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — high-resolution crystal structure with functional site mapping\",\n      \"pmids\": [\"18560148\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CXCL10 signals through TLR4 (not solely CXCR3) on pancreatic β-cells to decrease viability and impair insulin secretion; CXCL10 induces sustained activation of Akt, JNK, and cleavage of PAK-2, switching Akt signaling from proliferation to apoptosis.\",\n      \"method\": \"Human islet treatment with recombinant CXCL10, TLR4 identification as receptor, Akt/JNK/PAK-2 phosphorylation assays, apoptosis assay, insulin secretion measurement\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — signaling pathway dissection in primary human islets with multiple biochemical readouts; single lab\",\n      \"pmids\": [\"19187771\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CXCL10 inhibits endothelial cell proliferation through a CXCR3-independent mechanism; this inhibitory activity correlates with CXCL10's glycosaminoglycan (heparin) binding affinity rather than CXCR3 binding/signaling, as demonstrated using CXCL10 mutant panel analysis and CXCR3-deficient mouse endothelial cells.\",\n      \"method\": \"CXCR3 knockout mouse endothelial cells, CXCR3 neutralizing antibodies, CXCL10 mutant panel, FACS for CXCR3 expression, proliferation assay\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple orthogonal approaches (genetic KO, antibody blockade, structure-function mutant panel)\",\n      \"pmids\": [\"20856926\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CXCL10 repression in IPF lung fibroblasts involves histone deacetylation combined with histone H3 hypermethylation (via G9a/H3K9me3 and SUV39H1); this reduces transcription factor binding to the IP-10 promoter; HDAC or G9a inhibitors reverse both modifications and restore CXCL10 expression.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP), HDAC and G9a inhibitors, nuclear run-on, promoter transcription factor binding assays in IPF patient fibroblasts\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — ChIP with pharmacological rescue in patient-derived cells; multiple epigenetic marks interrogated\",\n      \"pmids\": [\"20404089\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CXCL10 acting via CXCR3 promotes synovial fibroblast invasion through MMP-1 production, intracellular calcium influx, and actin cytoskeleton reorganization with lamellipodia formation; CXCR3 blockade reduces invasiveness by up to 77% in arthritic rat FLS and 58% in RA patient FLS.\",\n      \"method\": \"Matrigel invasion assay, anti-CXCR3 antibody, CXCR3 inhibitor AMG487, MMP ELISA, intracellular calcium assay, actin cytoskeleton imaging in primary FLS\",\n      \"journal\": \"Arthritis and rheumatism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal functional assays in primary patient-derived cells with defined signaling pathway\",\n      \"pmids\": [\"21811993\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"CXCL10 mediates macrophage differentiation of activated B cells into plasma cells through a novel dialog: macrophage-derived CXCL10 (induced by B cell-derived IL-6 via STAT3 phosphorylation) drives B cell differentiation into CD138+CD38++ plasma cells, and CXCL10 amplifies IL-6 production by B cells sustaining the STAT3-mediated differentiation signal; IP-10-deficient mice show reduced NP-specific plasma cells.\",\n      \"method\": \"Human tonsil macrophage isolation, monocyte-derived macrophage co-culture with B cells, CXCL10 neutralization, STAT3 inhibition, IP-10-deficient mouse immunization model\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal neutralization, genetic KO in vivo model, and mechanistic signaling in primary human cells\",\n      \"pmids\": [\"22987802\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"CXCL10 promotes osteolytic bone metastasis by facilitating CXCR3-expressing cancer cell recruitment to bone, promoting cancer cell adhesion to type I collagen, and augmenting RANKL-mediated osteoclast formation; cancer-bone colonization further amplifies host CXCL10 production via direct cancer cell–macrophage contact.\",\n      \"method\": \"Neutralizing CXCL10 antibody, CXCR3 knockout mice, in vivo bone metastasis model, adhesion assay to collagen I, osteoclast differentiation assay\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic and antibody loss-of-function in vivo with mechanistic in vitro follow-up\",\n      \"pmids\": [\"22562465\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"CXCL10-CXCR3 axis mediates neutrophil-driven fulminant lung injury (ARDS); CXCL10 is produced by infiltrating pulmonary neutrophils via TRIF-dependent signaling; CXCL10-CXCR3 acts in an autocrine fashion on neutrophil oxidative burst and chemotaxis, amplifying pulmonary inflammation. CXCL10- or CXCR3-deficient mice show improved ARDS severity and survival.\",\n      \"method\": \"CXCL10 KO, CXCR3 KO, IFNAR1 KO, TRIF KO mice in acid-aspiration and influenza ARDS models; neutrophil CXCR3 expression analysis; in vivo survival studies\",\n      \"journal\": \"American journal of respiratory and critical care medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic KO models with in vivo phenotype and mechanistic signaling; highly cited\",\n      \"pmids\": [\"23144331\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"CXCL10 induction during HCV infection in hepatocytes proceeds via two independent, parallel pathways through TLR3 and RIG-I pattern recognition receptors; in pure hepatocyte cultures, CXCL10 induction is independent of type I and III IFNs, whereas non-parenchymal cell-derived IFNs contribute to CXCL10 induction in mixed PHH cultures; CXCL10 protein expression positively correlates with intracellular HCV Core antigen.\",\n      \"method\": \"TLR3/RIG-I functional or non-functional hepatocyte lines, IFN neutralization, immunodepletion of non-parenchymal cells, immunofluorescence correlation analysis\",\n      \"journal\": \"Journal of hepatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic and antibody dissection of parallel pathways in primary human hepatocytes and cell lines\",\n      \"pmids\": [\"23770038\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Heparanase induction decreases CXCL10 levels in myeloma cells, and CXCL10 exerts tumor-suppressor and anti-angiogenic properties; recombinant CXCL10 attenuates myeloma and HUVEC proliferation in vitro, and CXCL10 overexpression or CXCL10-Ig fusion protein treatment markedly reduces myeloma xenograft growth in vivo.\",\n      \"method\": \"Inducible Tet-on heparanase system, soft agar colony assay, xenograft model, recombinant CXCL10 treatment, CXCL10-Ig fusion protein in vivo\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — gain/loss of function with in vitro and in vivo endpoints in defined system\",\n      \"pmids\": [\"24699306\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"MRP8/MRP14 (endogenous DAMP) induces IP-10/CXCL10 production in monocytes/macrophages via TLR4 and TRIF (not MyD88); full induction requires synergistic activation of both NF-κB and IRF3 transcription factors; MRP8/MRP14-induced chemotaxis of CXCR3+ cells depends on IP-10 production; neutralizing anti-MRP8 antibody in vivo prevents NF-κB/IRF3 activation and IP-10 production.\",\n      \"method\": \"THP-1 monocytes, TLR4 and TRIF/MyD88 pathway inhibition, NF-κB and IRF3 activation assays, CXCR3+ cell chemotaxis, mouse trauma/hemorrhagic shock model with neutralizing antibody\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pathway dissection with genetic/pharmacological tools confirmed in vivo\",\n      \"pmids\": [\"25342131\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"MLK3 (mixed lineage kinase 3) mediates the release of CXCL10-laden extracellular vesicles from lipotoxic hepatocytes; CXCL10 is enriched in EVs from LPC-treated hepatocytes and colocalizes with EV marker CD63 in vesicular structures; MLK3 genetic deletion or pharmacological inhibition prevents CXCL10 enrichment in EVs; these CXCL10-bearing EVs induce macrophage chemotaxis, which is blocked by CXCL10-neutralizing antisera.\",\n      \"method\": \"Differential ultracentrifugation EV isolation, mass spectrometry, GFP-CXCL10/RFP-CD63 colocalization, MLK3 KO mice, MLK3 inhibitor, macrophage chemotaxis assay, CXCL10 neutralizing antisera\",\n      \"journal\": \"Hepatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution (EV isolation + functional assay) with genetic and pharmacological validation in vitro and in vivo; highly cited\",\n      \"pmids\": [\"26406121\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"CXCL10 promotes hepatocellular carcinoma EMT and metastasis through MMP-2 as a downstream effector; CXCL10 overexpression enhances migration, invasion, and metastasis of HCC cells in vitro and in vivo, while CXCL10 silencing inhibits these, and microarray analysis identified MMP-2 as a downstream target of CXCL10.\",\n      \"method\": \"CXCL10 overexpression and shRNA silencing, in vitro migration/invasion assay, in vivo metastasis model, microarray analysis, MMP-2 validation\",\n      \"journal\": \"American journal of translational research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — gain and loss of function with transcriptomic identification of downstream effector\",\n      \"pmids\": [\"28670372\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"CXCL10 stimulates IFN-γ-primed human monocytes to robustly produce IL-12 and IL-23 via CXCR3 receptor engagement and IκB kinase / p38 MAPK signaling pathways; in a murine colitis model, anti-CXCL10 antibody treatment suppresses local myeloid-derived inflammatory cytokine production and reduces intestinal tissue damage.\",\n      \"method\": \"Human monocyte culture, CXCR3 blocking antibody, IKK and p38 MAPK inhibitors, cytokine ELISA; innate murine colitis model with anti-CXCL10 treatment\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological pathway dissection in primary human cells with in vivo confirmation\",\n      \"pmids\": [\"28899907\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"CXCL10 suppresses corneal hem- and lymph-angiogenesis through downregulation of MMP-13 (and VEGFa/c); MMP-13 is required for neovascularization but does not affect CXCL10 expression; CXCL10 and CXCR3 neutralization promotes angiogenesis, while AAV9-driven epithelial CXCL10 overexpression suppresses it.\",\n      \"method\": \"AAV9 CXCL10 overexpression, CXCL10/CXCR3 neutralization, MMP-13 inhibition, mouse corneal infection/suture neovascularization models\",\n      \"journal\": \"Angiogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo gain/loss of function with genetic/pharmacological pathway placement\",\n      \"pmids\": [\"28623423\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"EZH2 and G9a cooperate and physically interact to epigenetically repress CXCL10 in IPF fibroblasts via H3K27me3 and H3K9me3 marks respectively; EZH2 knockdown reduces both EZH2/H3K27me3 and G9a/H3K9me3, and vice versa; TGF-β1 induces this interplay to repress CXCL10; EZH2/G9a inhibitors restore CXCL10 expression.\",\n      \"method\": \"ChIP, Re-ChIP, proximity ligation assay (EZH2-G9a interaction), siRNA knockdown, EZH2/G9a inhibitors, TGF-β1 treatment of primary fibroblasts\",\n      \"journal\": \"American journal of respiratory cell and molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — physical interaction (proximity ligation) plus reciprocal ChIP and genetic knockdown with functional restoration\",\n      \"pmids\": [\"29053336\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Viperin (RSAD2) regulates chondrogenic differentiation by influencing secretion of CXCL10, which in turn modulates TGF-β/SMAD2/3 activity; viperin-CXCL10-TGF-β/SMAD2/3 axis is disturbed in cartilage-hair hypoplasia (CHH) chondrocytes; viperin is expressed in differentiating chondrocytes and controls protein secretion.\",\n      \"method\": \"siRNA silencing of viperin, plasmid overexpression, label-free MS proteomics of secretome, CXCL10 ELISA, promoter reporter assay, TGF-β/SMAD2/3 signaling readouts, immunohistochemistry\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods establishing pathway axis, single lab\",\n      \"pmids\": [\"30718282\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Leishmania major virulence factor GP63 cleaves CXCL10 after amino acid A81 at the base of its C-terminal α-helix, inactivating it; GP63 shows specificity for CXCR3-binding chemokines (CXCL10 and homologs) but not CXCL8 or CCL22; cleaved CXCL10 cannot signal through CXCR3 and fails to support T cell chemotaxis in vitro; cleavage is produced by both extracellular promastigotes and intracellular amastigotes.\",\n      \"method\": \"Recombinant GP63 cleavage assay, mass spectrometry cleavage site mapping, CXCR3 chemotaxis assay, substrate specificity panel with multiple chemokines, amastigote/promastigote stage-specific analysis\",\n      \"journal\": \"Frontiers in cellular and infection microbiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — precise cleavage site identified by MS, specificity panel, functional chemotaxis consequence demonstrated\",\n      \"pmids\": [\"31440475\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"hCG inhibits CXCL10 expression in endometrial stromal/decidual cells by inducing EZH2-mediated H3K27me3 histone methylation at Region 4 of the CXCL10 promoter; hCG-mediated CXCL10 suppression reduces CD8 T cell recruitment to decidua.\",\n      \"method\": \"In vitro decidual cell treatment with hCG, ChIP for H3K27me3, EZH2 inhibition, CXCL10 promoter deletion analysis, CD8 T cell migration assay\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP with EZH2 inhibition and functional T cell recruitment readout\",\n      \"pmids\": [\"32238853\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Plasmodium falciparum inhibits CXCL10 synthesis in monocytes by disrupting ribosome association with CXCL10 transcripts (translational suppression); the underlying mechanism involves RNA cargo delivery into monocytes triggering RIG-I, leading to HuR binding to an AU-rich domain in the CXCL10 3′UTR; conversely, high CXCL10 levels signal P. falciparum to accelerate growth as a survival strategy.\",\n      \"method\": \"Ribosome profiling/polysome analysis, RNA cargo delivery assay, RIG-I signaling assay, RIP assay (HuR binding to CXCL10 3′UTR), AU-rich element identification, parasite growth acceleration assay\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mechanistic dissection at translational level with multiple molecular tools identifying specific 3′UTR element and RNA-binding protein\",\n      \"pmids\": [\"34381047\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"MEK inhibitor combined with PEM/CDDP chemotherapy triggers CXCL10 secretion from cancer cells through optineurin (OPTN)-dependent mitophagy, mitochondrial DNA release, and TLR9 signaling; TLR9 or autophagy/mitophagy inhibition abolishes CXCL10 induction and anti-tumor efficacy.\",\n      \"method\": \"Drug screening, OPTN KO, TLR9 inhibition, mitophagy inhibitors, mitochondrial DNA depletion, CXCL10 ELISA, in vivo lung tumor models\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic and pharmacological loss-of-function tools establishing pathway in vivo and in vitro; highly cited\",\n      \"pmids\": [\"35051357\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"MLKL regulates macrophage M1 polarization in acute pancreatitis through CXCL10 secretion from pancreatic acinar cells; MLKL knockout attenuates AP and reduces M1 macrophage polarization; neutralization of CXCL10 in vitro impairs conditioned-medium-driven M1 polarization, and in vivo CXCL10 neutralization reduces M1 macrophage polarization and AP severity; MLKL acts independently of RIPK3 in this pathway.\",\n      \"method\": \"Mlkl KO and Ripk3 KO mice, cerulein/LPS AP model, primary acinar cell isolation, conditioned medium, CXCL10 neutralizing antibody in vitro and in vivo, macrophage polarization assays\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO and antibody neutralization with defined cellular phenotype in vivo and in vitro\",\n      \"pmids\": [\"36828808\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CXCL10 (IP-10) is an IFN-γ–inducible CXC chemokine that signals primarily through CXCR3 (including the alternatively spliced angiostatic CXCR3-B isoform) and, in certain contexts, through TLR4; oligomerization and glycosaminoglycan binding are required for endothelial cell presentation and in vivo T cell recruitment; the protein is subject to N-terminal truncation by CD26/DPPIV and C-terminal cleavage by pathogen proteases (e.g., Leishmania GP63) that abrogate CXCR3 signaling; its expression is epigenetically repressed by cooperative EZH2/G9a-mediated histone methylation and HDAC-mediated deacetylation at its promoter; upstream induction proceeds via parallel TLR3/RIG-I or TLR4/TRIF pathways converging on NF-κB and IRF3; CXCL10 orchestrates Th1 polarization, antiangiogenesis, fibroblast migration inhibition, plasma cell differentiation, neutrophil autocrine amplification in ARDS, and osteoclastogenesis, while also being packaged into MLK3-dependent extracellular vesicles from lipotoxic hepatocytes to drive macrophage chemotaxis.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"CXCL10 (IP-10) is an interferon-γ-inducible CXC chemokine that orchestrates immune cell recruitment, angiostasis, and tissue remodeling by signaling through CXCR3 on activated T cells and NK cells, while also exerting receptor-independent effects via glycosaminoglycan binding and non-canonical receptor engagement. CXCL10 signals through CXCR3-A to promote Th1 polarization (upregulating T-bet and IFN-γ), induce IL-12/IL-23 from monocytes via IκB kinase and p38 MAPK, and drive plasma cell differentiation through an IL-6/STAT3 feedback loop with macrophages [PMID:16337473, PMID:28899907, PMID:22987802]; it also signals independently of CXCR3 through TLR4 in pancreatic β-cells to switch Akt signaling toward apoptosis [PMID:19187771], and inhibits endothelial proliferation through glycosaminoglycan binding rather than CXCR3 [PMID:20856926]. Functional oligomerization is required for endothelial presentation and in vivo T-cell recruitment, as a monomeric mutant retains in vitro chemotactic activity but fails to recruit T cells in vivo [PMID:17082614, PMID:18560148]. CXCL10 transcription is subject to epigenetic silencing via cooperative EZH2 (H3K27me3) and G9a (H3K9me3) histone methylation at its promoter—a mechanism operative in pulmonary fibrosis and at the maternal–fetal interface—and its mRNA is post-transcriptionally suppressed by HuR binding to its 3′UTR upon RIG-I activation [PMID:29053336, PMID:20404089, PMID:34381047].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"Identification of CXCR3 as the shared receptor for CXCL10 and Mig on activated T cells established the molecular basis for selective chemotaxis of stimulated—but not resting—lymphocytes, and linked CXCL10 to angiostatic and hematopoietic-inhibitory activities.\",\n      \"evidence\": \"Reciprocal desensitization and chemotaxis assays with recombinant CXCL10 on activated T cells\",\n      \"pmids\": [\"9060447\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream intracellular signaling pathways not yet mapped\", \"Relative contributions of CXCR3 isoforms undefined\", \"In vivo receptor dependence not directly tested\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Loss-of-function and gain-of-function mouse genetics demonstrated that CXCL10 is a physiological anti-fibrotic factor that limits fibroblast migration into the lung, resolving whether its in vitro angiostatic/chemotactic properties had in vivo disease relevance.\",\n      \"evidence\": \"CXCL10-knockout and IP-10-transgenic mice in bleomycin pulmonary fibrosis model with fibroblast chemotaxis assays\",\n      \"pmids\": [\"15205180\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor (CXCR3 vs GAG) mediating fibroblast inhibition not defined\", \"Mechanism of fibroblast migration inhibition not molecularly resolved\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Demonstration that CXCL10 acting through CXCR3-A upregulates T-bet and IFN-γ while suppressing GATA-3 and Th2 cytokines established CXCL10 as an active Th1-polarizing signal, not merely a chemoattractant.\",\n      \"evidence\": \"Antigen-specific human CD4+ T-cell lines with anti-CXCR3 neutralization, cytokine/transcription factor profiling\",\n      \"pmids\": [\"16337473\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signaling intermediates between CXCR3-A and T-bet induction not identified\", \"In vivo Th1 skewing by CXCL10 not directly shown\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"The discovery that CXCL10 oligomerization is essential for endothelial presentation and in vivo T-cell recruitment—while dispensable for in vitro chemotaxis—revealed that GAG-dependent immobilization of oligomeric CXCL10 is the rate-limiting step for physiological function.\",\n      \"evidence\": \"Engineered monomeric CXCL10 mutant tested in vitro (chemotaxis, endothelial binding) and in vivo (intratracheal CD8+ T-cell recruitment)\",\n      \"pmids\": [\"17082614\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Oligomeric state required in vivo (dimer vs tetramer) not resolved\", \"Structural basis for GAG-dependent presentation not fully defined\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Crystal structure of CXCL10 revealed a novel tetrameric architecture with mapped heparin- and receptor-binding surfaces, providing the structural framework for understanding why oligomerization and GAG binding are functionally required.\",\n      \"evidence\": \"X-ray crystallography of murine CXCL10 with heparin- and receptor-binding residue mapping\",\n      \"pmids\": [\"18560148\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structure of human CXCL10 tetramer not determined\", \"Atomic-level CXCR3-CXCL10 complex structure unavailable\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Discovery of TLR4-dependent, CXCR3-independent CXCL10 signaling in pancreatic β-cells—switching Akt from proliferative to apoptotic via PAK-2 cleavage—overturned the assumption that CXCL10 acts exclusively through CXCR3.\",\n      \"evidence\": \"Human islet stimulation with recombinant CXCL10, TLR4 identification, Akt/JNK/PAK-2 signaling analysis\",\n      \"pmids\": [\"19187771\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct binding of CXCL10 to TLR4 not demonstrated biochemically\", \"Relevance to other TLR4-expressing cell types untested\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Two independent studies established dual mechanisms of CXCL10 gene regulation and receptor-independent function: CXCL10 inhibits endothelial proliferation through GAG binding independent of CXCR3, and CXCL10 transcription is epigenetically silenced in fibrotic fibroblasts via histone deacetylation and H3 methylation by G9a/SUV39H1.\",\n      \"evidence\": \"CXCR3-KO endothelial cells and CXCL10 mutant panels for GAG dependence; ChIP with multiple histone marks plus pharmacologic rescue in IPF fibroblasts\",\n      \"pmids\": [\"20856926\", \"20404089\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the GAG-dependent 'receptor' mediating anti-proliferative signaling unknown\", \"Upstream signals driving epigenetic remodeling in IPF not fully characterized\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"CXCL10 was placed at the center of a macrophage–B cell IL-6/STAT3 positive-feedback loop driving plasma cell differentiation, extending its functional role beyond T-cell/NK-cell chemotaxis to humoral immunity; IP-10-deficient mice had reduced plasma cell numbers and antibody titers.\",\n      \"evidence\": \"Human macrophage/B-cell co-culture with CXCL10 neutralization, IP-10-deficient mouse immunization\",\n      \"pmids\": [\"22987802\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CXCL10 acts directly on B cells or exclusively via macrophages not fully resolved\", \"Signaling from CXCR3 in B cells not characterized\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Multiple studies defined upstream transcriptional control of CXCL10: DAMP-driven (MRP8/14) CXCL10 induction requires TLR4–TRIF-dependent cooperative NF-κB and IRF3 activation, while EGFR signaling suppresses IRF1-dependent CXCL10 production during viral infection.\",\n      \"evidence\": \"TLR4/TRIF/MyD88 pathway dissection with inhibitors and siRNA in monocytes; EGFR inhibitor treatment during respiratory virus infection in epithelial cells\",\n      \"pmids\": [\"25342131\", \"24838750\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Integration of NF-κB/IRF3/IRF1 at the CXCL10 promoter in chromatin context not resolved\", \"EGFR–IRF1 mechanism is pharmacologic, not genetic\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Multiple parallel discoveries clarified CXCL10's downstream effector functions: it induces IL-12/IL-23 from monocytes via IKK/p38 MAPK, promotes M1 macrophage polarization from fibroblast-derived signals, drives hepatocellular carcinoma EMT/metastasis through MMP-2, and suppresses corneal neovascularization by downregulating VEGF and MMP-13.\",\n      \"evidence\": \"CXCR3 and p38 inhibitor studies in monocytes plus anti-CXCL10 in colitis model; CXCL10 neutralization in fibroblast–macrophage co-culture; CXCL10 overexpression/silencing in HCC cells; AAV9-CXCL10 corneal overexpression with MMP-13 inhibition\",\n      \"pmids\": [\"28899907\", \"31394157\", \"28670372\", \"28623423\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CXCR3-A vs CXCR3-B mediates monocyte IL-12 induction not tested\", \"Distinction between direct vs indirect CXCL10 effects on EMT unclear\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Re-ChIP and proximity ligation assays demonstrated that EZH2 and G9a physically interact and function interdependently at the CXCL10 promoter, establishing that dual H3K27me3/H3K9me3 deposition is the mechanistic basis for TGF-β1-driven CXCL10 silencing in fibrosis.\",\n      \"evidence\": \"Re-ChIP, PLA, EZH2/G9a siRNA knockdown and pharmacologic inhibition in IPF fibroblasts and TGF-β1-treated normal fibroblasts\",\n      \"pmids\": [\"29053336\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether EZH2–G9a interaction is direct or scaffold-mediated not determined\", \"Genome-wide co-regulation by this complex beyond CXCL10 not assessed\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identification of Leishmania GP63-mediated cleavage of CXCL10 at A81 (inactivating CXCR3 signaling) revealed a pathogen immune-evasion strategy that targets the C-terminal α-helix essential for receptor engagement.\",\n      \"evidence\": \"Recombinant GP63 cleavage, mass spectrometry for site mapping, CXCR3 signaling and T-cell chemotaxis with cleaved vs intact CXCL10\",\n      \"pmids\": [\"31440475\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether other pathogen proteases cleave at the same site is unknown\", \"Structural basis for C-terminal helix requirement in CXCR3 activation not resolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Discovery that P. falciparum RNA triggers RIG-I, leading to HuR binding to the CXCL10 3′UTR and translational suppression, established a post-transcriptional layer of CXCL10 regulation distinct from the well-characterized transcriptional and epigenetic mechanisms.\",\n      \"evidence\": \"Monocyte RNA transfection, RIG-I pathway analysis, HuR–3′UTR binding, polysome profiling\",\n      \"pmids\": [\"34381047\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Identity of the specific AU-rich element in the 3′UTR bound by HuR not mapped at nucleotide resolution\", \"Generalizability to non-parasitic RIG-I activation not tested\", \"Single study without independent replication\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Linking OPTN-dependent mitophagy to TLR9-dependent CXCL10 secretion showed that mitochondrial DNA released during mitophagy provides an innate immune trigger for CXCL10, connecting cellular quality-control machinery to adaptive immune recruitment of CD8+ T cells.\",\n      \"evidence\": \"Drug combination screening, OPTN/TLR9 genetic inhibition, mitophagy assays, CXCL10 ELISA, in vivo CD8+ T-cell recruitment in NSCLC models\",\n      \"pmids\": [\"35051357\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether mtDNA directly activates TLR9 to induce CXCL10 or acts through intermediaries not fully resolved\", \"Quantitative contribution relative to IFN-γ-dependent CXCL10 induction unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the atomic structure of the CXCL10–CXCR3 signaling complex, the molecular identity of the GAG-dependent receptor mediating CXCR3-independent anti-proliferative effects on endothelial cells, and the relative in vivo contributions of transcriptional, epigenetic, and post-transcriptional regulatory layers to CXCL10 bioavailability in specific disease contexts.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No CXCL10–CXCR3 co-crystal or cryo-EM structure\", \"GAG-dependent anti-proliferative receptor unidentified\", \"No integrated in vivo model assessing epigenetic vs post-transcriptional regulation simultaneously\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0, 5, 6, 9, 17]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [4, 12, 20, 28]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 1, 6, 17, 24]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0005215\", \"supporting_discovery_ids\": []},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 5, 6, 9, 24]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [3, 7, 9, 18]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"CXCR3\",\n      \"TLR4\",\n      \"EZH2\",\n      \"G9a\",\n      \"HuR\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"CXCL10 (IP-10) is an interferon-inducible CXC chemokine that functions as a central mediator of Th1-type immune responses, angiostasis, and tissue remodeling by signaling primarily through CXCR3 on activated T cells, NK cells, monocytes, and other CXCR3-expressing cell types, while also acting as a natural antagonist of the Th2-associated receptor CCR3 [PMID:9060447, PMID:11110785, PMID:16337473]. Oligomerization is required for glycosaminoglycan-dependent endothelial presentation and in vivo T-cell recruitment, whereas CXCL10's angiostatic activity on endothelial cells is mediated through the CXCR3-B splice variant and, independently, through glycosaminoglycan binding [PMID:17082614, PMID:12782716, PMID:20856926]. Transcriptional induction proceeds via parallel TLR3/RIG-I or TLR4/TRIF pathways converging on NF-κB and IRF3, while epigenetic silencing involves cooperative EZH2/G9a-mediated histone methylation and HDAC-dependent deacetylation at the CXCL10 promoter; post-translationally, N-terminal truncation by CD26/DPPIV and C-terminal cleavage by the Leishmania protease GP63 abrogate CXCR3 signaling [PMID:25342131, PMID:15315758, PMID:29053336, PMID:11390394, PMID:31440475]. Beyond canonical chemotaxis, CXCL10 drives macrophage-dependent plasma cell differentiation, promotes osteoclastogenesis, amplifies neutrophil oxidative burst in an autocrine CXCR3 loop during ARDS, inhibits fibroblast migration to limit pulmonary fibrosis, and is released in MLK3-dependent extracellular vesicles from lipotoxic hepatocytes to recruit macrophages [PMID:22987802, PMID:22562465, PMID:23144331, PMID:15205180, PMID:26406121].\",\n  \"teleology\": [\n    {\n      \"year\": 1985,\n      \"claim\": \"The discovery of IP-10 as an IFN-γ-inducible early-response gene established CXCL10 as a primary interferon effector and placed it within the CXC chemokine family, providing the molecular identity needed for all subsequent functional studies.\",\n      \"evidence\": \"Molecular cloning, Northern blot, and nuclear run-on assay in IFN-γ-treated cells\",\n      \"pmids\": [\"3925348\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor unknown at this point\", \"No functional role defined beyond inducibility\", \"Protein structure not determined\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Identification of CXCR3 as the shared receptor for CXCL10, CXCL9, and CXCL11 resolved the receptor-specificity question and explained the selective chemotaxis for activated (but not resting) T cells.\",\n      \"evidence\": \"Recombinant protein chemotaxis assays, desensitization experiments, and receptor-sharing functional studies\",\n      \"pmids\": [\"9060447\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"CXCR3 splice variants not yet recognized\", \"Downstream signaling pathways uncharacterized\", \"In vivo relevance of receptor specificity not demonstrated\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Demonstrating that CXCL10 acts as a pure antagonist of the Th2 receptor CCR3 without inducing internalization revealed a dual mechanism—agonism at CXCR3 and antagonism at CCR3—that positions CXCL10 as a regulator of Th1/Th2 balance beyond simple chemotaxis.\",\n      \"evidence\": \"Radioligand competition binding, chemotaxis, Ca²⁺ mobilization, and receptor internalization assays\",\n      \"pmids\": [\"11110785\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological significance of CCR3 antagonism in vivo not established\", \"Structural basis for dual receptor interaction unknown\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Discovery of the CXCR3-B splice variant as the receptor mediating CXCL10's angiostatic activity resolved the apparent paradox of how the same chemokine promotes T-cell chemotaxis via CXCR3-A yet inhibits endothelial cell growth via distinct signaling.\",\n      \"evidence\": \"Receptor reconstitution with CXCR3-A vs CXCR3-B transfection, DNA synthesis, and apoptosis assays\",\n      \"pmids\": [\"12782716\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of CXCR3-B vs GAG binding to angiostasis not resolved\", \"CXCR3-B downstream signaling not fully mapped\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Systematic CXCR3 domain mutagenesis and the demonstration that κB site sequence determines NF-κB cofactor specificity at the CXCL10 promoter defined the receptor-proximal and transcriptional regulatory logic governing CXCL10 signaling and expression.\",\n      \"evidence\": \"CXCR3 domain deletion/mutation analysis with β-arrestin dominant-negative; κB site swapping experiments\",\n      \"pmids\": [\"15150261\", \"15315758\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full signal transduction cascade from CXCR3 to effector functions not mapped\", \"Chromatin-level regulation not yet addressed\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Proving that CXCL10 oligomerization is required for endothelial presentation and in vivo T-cell recruitment—despite a monomeric mutant retaining in vitro chemotactic activity—established that quaternary structure gates physiological function.\",\n      \"evidence\": \"Monomeric CXCL10 mutant tested in vitro chemotaxis, intratracheal mouse instillation, and transendothelial migration assays\",\n      \"pmids\": [\"17082614\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Oligomer stoichiometry required in vivo not defined\", \"Relationship between oligomerization and GAG binding not fully disentangled\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"The crystal structure of mouse CXCL10 revealing a novel tetramer with heparin-binding sites at dimer interfaces provided the first atomic framework for understanding oligomer-dependent GAG presentation.\",\n      \"evidence\": \"X-ray crystallography with surface mapping of heparin- and receptor-binding residues\",\n      \"pmids\": [\"18560148\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Human CXCL10 structure in complex with CXCR3 not available\", \"Higher-order oligomers on GAG surfaces not structurally resolved\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Identification of TLR4 as an alternative CXCL10 receptor on pancreatic β-cells that switches Akt signaling from proliferative to apoptotic expanded the receptor repertoire beyond CXCR3 and revealed context-dependent signaling outcomes.\",\n      \"evidence\": \"Recombinant CXCL10 treatment of human islets, TLR4 identification, Akt/JNK/PAK-2 phosphorylation and apoptosis assays\",\n      \"pmids\": [\"19187771\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"TLR4 as a direct CXCL10 receptor awaits independent replication\", \"Structural basis for CXCL10–TLR4 binding unknown\", \"Relative contribution of TLR4 vs CXCR3 on β-cells not quantified\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Demonstrating that CXCL10's antiproliferative effect on endothelial cells is CXCR3-independent and correlates with GAG-binding affinity, together with the discovery that cooperative EZH2/G9a histone methylation and HDAC-dependent deacetylation silence CXCL10 in fibrotic lung fibroblasts, defined both receptor-independent functional and epigenetic regulatory mechanisms.\",\n      \"evidence\": \"CXCR3 KO endothelial cells plus mutant panel; ChIP with HDAC/G9a inhibitor rescue in IPF fibroblasts\",\n      \"pmids\": [\"20856926\", \"20404089\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the GAG-dependent receptor or mechanism on endothelial cells not determined\", \"In vivo relevance of epigenetic silencing for fibrosis progression not causally tested\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Three studies collectively broadened CXCL10's effector biology: it drives macrophage-dependent B-cell-to-plasma-cell differentiation through a CXCL10–IL-6–STAT3 feedforward loop, promotes osteoclastogenesis in bone metastasis, and amplifies ARDS through an autocrine CXCR3 loop on neutrophils—demonstrating roles far beyond T-cell chemotaxis.\",\n      \"evidence\": \"Macrophage/B-cell co-culture with CXCL10 neutralization and IP-10 KO mice; CXCR3 KO mice in bone metastasis model; CXCL10/CXCR3/TRIF KO mice in acid aspiration and influenza ARDS models\",\n      \"pmids\": [\"22987802\", \"22562465\", \"23144331\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"CXCL10's role in plasma cell differentiation in non-immunization settings not tested\", \"Autocrine neutrophil loop specificity vs other CXCR3 ligands not fully delineated\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Discovery that lipotoxic hepatocytes release CXCL10 in MLK3-dependent extracellular vesicles that recruit macrophages revealed a vesicular delivery mode for this chemokine, distinct from conventional secretion.\",\n      \"evidence\": \"EV isolation, GFP-CXCL10/RFP-CD63 colocalization, MLK3 KO mice, macrophage chemotaxis assay with CXCL10-neutralizing antisera\",\n      \"pmids\": [\"26406121\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Proportion of CXCL10 delivered via EVs vs soluble secretion in vivo unknown\", \"EV-CXCL10 receptor engagement mechanism on macrophages not defined\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Demonstrating that EZH2 and G9a physically interact and reciprocally depend on each other to co-silence CXCL10 via H3K27me3 and H3K9me3 under TGF-β1 defined the full epigenetic repression complex and its upstream signal.\",\n      \"evidence\": \"Re-ChIP, proximity ligation assay, reciprocal siRNA knockdown, EZH2/G9a inhibitors in primary IPF fibroblasts\",\n      \"pmids\": [\"29053336\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether this EZH2/G9a complex is recruited by specific DNA-binding factors remains unknown\", \"Generalizability beyond fibroblasts not established\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identification of Leishmania GP63 as a specific C-terminal protease that cleaves CXCL10 after A81 to abolish CXCR3 signaling established pathogen-mediated inactivation as a immune evasion strategy, complementing the known N-terminal truncation by CD26/DPPIV.\",\n      \"evidence\": \"Recombinant GP63 cleavage, mass spectrometry site mapping, chemokine specificity panel, CXCR3 chemotaxis assay\",\n      \"pmids\": [\"31440475\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo contribution of GP63-mediated CXCL10 cleavage to Leishmania pathogenesis not quantified\", \"Whether host proteases cleave at the same C-terminal site is unknown\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Demonstrating that Plasmodium falciparum suppresses CXCL10 translation through RNA cargo-triggered RIG-I/HuR binding to the CXCL10 3′UTR AU-rich element revealed a post-transcriptional immune evasion mechanism distinct from transcriptional or proteolytic regulation.\",\n      \"evidence\": \"Ribosome profiling, RIP assay for HuR–CXCL10 3′UTR binding, RIG-I pathway dissection\",\n      \"pmids\": [\"34381047\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the RNA cargo species from P. falciparum not defined\", \"Whether HuR-mediated translational suppression extends to other CXCR3 ligands not tested\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Linking MEK inhibitor/chemotherapy-induced CXCL10 secretion to optineurin-dependent mitophagy, mitochondrial DNA release, and TLR9 signaling established an entirely new induction pathway originating from mitochondrial stress rather than canonical interferon signaling.\",\n      \"evidence\": \"OPTN KO, TLR9 inhibition, mitophagy inhibitors, mitochondrial DNA depletion, in vivo lung tumor models\",\n      \"pmids\": [\"35051357\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether this pathway operates in non-cancer cell types unknown\", \"Relative contribution of mitophagy-derived vs IFN-driven CXCL10 in tumors not quantified\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Major unresolved questions include the identity of the receptor mediating CXCR3-independent angiostatic signaling via GAG binding, the structural basis of CXCL10–CXCR3 and CXCL10–TLR4 interactions, and whether EV-packaged CXCL10 engages receptors differently from the soluble form.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No co-crystal structure of CXCL10 with any receptor\", \"GAG-dependent antiproliferative receptor on endothelial cells unidentified\", \"In vivo quantitative partitioning between EV-bound and soluble CXCL10 unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0, 3, 6, 11, 16, 18, 24, 25, 26]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [6, 21]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 1, 18, 19, 30]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [30]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [3, 5, 16, 24, 26, 29, 32, 38]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [4, 11, 12, 20, 23]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [14, 22, 34, 37]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [22, 34, 37]},\n      {\"term_id\": \"R-HSA-5653656\", \"supporting_discovery_ids\": [30]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"CXCR3\",\n      \"CCR3\",\n      \"TLR4\",\n      \"DPP4\",\n      \"EZH2\",\n      \"G9a\",\n      \"HuR\",\n      \"MLK3\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}